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“Equipped with this modern knowledge, I have, returning through the little 
death from my earlier lives, been able to compare the heavens then and now. 
And the stars do change. I have seen pole stars and pole stars and dynasties 
of pole stars. The pole star to-day is in Ursa Minor. Yet, in those far days I 
have seen the pole star in Draco, in Hercules, in Vega, in Cygnus, and in 
Cepheus. No; not even the stars abide, and yet the memory and the knowledge 
of them abides in me, in the spirit of me that is memory and that is eternal. 
Only spirit abides. All else, being mere matter, passes, and must pass.” 
 
Jack London  
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! ABSTRACT !!
Infectious diseases account for one fifth of global mortality. Although many efforts have 
been made to prevent and treat specific viral diseases (e.g. hepatitis B, AIDS) with vaccines 
and drugs, we still lack effective and biocompatible broad-spectrum antiviral agents, 
especially against re-emerging (e.g. Dengue virus) and newly emerging viruses (e.g. Ebola 
virus). Current advances in nanotechnology opened new frontiers in developing novel 
antivirals that can interact and inactivate a large number of viral pathogens. Nanoparticles 
(NPs) – particles in the size range 1-100 nm – can be finely engineered on their surface to 
interfere with key events of infections shared by many viruses, above all the attachment to 
the host cell. The aim of the present work is to assess the role of gold nanoparticles (Au-
NPs) capped with sulfonate molecules as potential inhibitors toward human viruses binding 
sulfated polysaccharides on the cell membrane. Results showed that sulfonated NPs have 
powerful antiviral as well as virucidal activity. Their applications may lead to substantial 
improvements in virus-spread control not only as novel wide-spectrum therapeutic agents 
but most importantly as novel active materials to be employed in emergency situations, for 
example in personal protective equipment, waste management, virus containment.  
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! I. INTRODUCTION 
Chapter 1 !
1.1!Viruses: structure and life cycle  !
Viruses are obligatory intracellular parasites that critically rely on the presence of a host to 
replicate and generate new virus progeny. They can be considered as nanoscopic (20-200nm) 
Trojan horses evolved to hijack cell synthetic machinery and transfer their genome into the 
cytosol or the nucleus of the cell (Smith & Helenius 2004; Marsh & Helenius 2006). In fact, 
they are able to activate endogenous cellular responses that allow their entry and the 
subsequent integration of their genes for initiating productive infection. Viruses are made of 
nucleic acids (RNA or DNA) enclosed in a shell of tightly packed proteins, called capsid 
(Marsh & Helenius 2006). They can be divided in two groups, based on whether they are 
surrounded by a lipid bilayer membrane originating from the cell membrane of the host cell 
(enveloped viruses), or non-enveloped viruses, that only have a protein exterior (Jolly & 
Sattentau 2013). Other structural components of viruses can be matrix proteins, membrane 
glycoproteins or enzymes (i.e. reverse transcriptase) (Marsh & Helenius 2006). Given the 
differences in morphology, structural composition and tropism the process of viral infection 
is extremely dynamic and consists of multiple steps: 1) the attachment of the virion to the 
cell surface followed by specific binding to receptors, 2) the penetration into the cell,  3) the 
uncoating, 4) the biosynthesis which comprises replication of the genome, transcription and 
translation, 5) the assembly of viral particles in infected cells, and 6) the extracellular release 
of newly formed viruses (Smith & Helenius 2004). The main phases of virus infective cycle 
are depicted in Figure 1.  
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Figure 1. The replicative cycle of retroviruses 
The figure illustrates the main steps of retrovirus (e.g. Human immunodeficiency virus-(HIV) 
replication, numbered from 1 to 6. (1) Virus binds to the attachment factor  (heparan sulfate 
proteoglycans (HSPGs)) via its surface glycoprotein, gp120; HIV interacts with specific entry 
receptors (CD4) and co-receptors (CCR5) and fuses (2) with the host cell membrane; (3) Uncoating 
of the viral capsid and release of viral genome (RNA) and proteins into the cytoplasm; (4) 
Biosynthesis, retrotranscription of the viral RNA, integration of the pre-integration complex (PIC) 
into the nucleus, transcription and translation of the HIV RNA and proteins. (5) Assembly of new 
viruses and (6) release and maturation of new infectious virions. Image modified from (Barré-
Sinoussi et al. 2013) Nature Review Microbiology. (2013) © Macmillan Publishers Limited. 
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1.2 Virus attachment and recognition of target cells !
In order to initiate a productive infection, viruses must first attach themselves to the surface 
of a host cell (Smith & Helenius 2004). Despite the differences among the wide range of 
viruses identified to date, all of them carry external structures, usually proteins, on their outer 
surface that enable the attachment and consequent recognition of target cells. Interactions 
between viruses and cell are mediated by two different kinds of molecules: 1) attachment 
factors, such as heparan sulfates or other carbohydrate structures on the cell surface and 2) 
entry receptors. The former merely serves to immobilize the particles on the cell surface in 
close proximity to the receptor, whereas the latter promotes viral entry into a cell by inducing 
conformational changes and activating signalling pathways. Recently, numerous viral 
attachment factors and entry receptors have been identified (Jolly & Sattentau 2013) and the 
crystal structures of several viruses and viral proteins have been solved (Kwong et al. 1998; 
Rossmann et al. 2002; Skehel & Wiley 2000). The association between viral proteins and 
attachment factors is reversible and thus make the attachment a relatively nonspecific 
process. Since viruses may encounter unfavourable conditions for cellular attachment (e.g. 
presence of competitive ligand) they have evolved to limit random three-dimensional 
propagation to quickly bind to the cell glycocalyx, the first physical structure encountered 
once cell surface is approached (Jolly & Sattentau 2013). The glycocalyx is a ubiquitous 
coating of carbohydrates conjugated to proteins (glycoproteins) and lipids (glycolipids), 
expressed on cell plasma membranes. The glycocalyx contains negatively charged moieties 
given by a group of glycoproteins called proteoglycans. Hence, the two major targets for 
viral attachment are glycoproteins and glycolipids (Jolly & Sattentau 2013). 
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1.2.1 Role of Heparan sulfate proteoglycans (HSPGs) in the attachment 
process !
Amongst the attachment factors, heparan sulfate proteoglycans (HSPGs) are frequently 
involved during the initial virus/cell interactions. They are ubiquitously expressed as part of 
the glycocalyx on cell surfaces and in the extracellular matrix. HSPGs are composed of a 
core protein and several heparan sulfate (HS) glycosaminoglycan (GAG) chains which are 
linear carbohydrate polymers of repeating disaccharides of glucosamine units (N-
acetylglucosamine or N-sulfated glucosamine) and -uronic acids (glucuronic or iduronic 
acids) (Bishop et al. 2007) (Figure 2). 
 
 
 
 
 
 
 
 
 
Figure 2.Structure of heparan-sulfate proteoglycans (HSPGs). 
HSPGs consist of a core protein (red lines) and one or more covalently liked heparan sulfate (HS) 
glycosaminoglycans (GAG) chains. Zooming in further, HSGAG are composed of disaccharide units 
of uronic acid linked to glucosamine. Each disaccharide unit can be sulfated at different positions of 
the uronic acid and/or the glucosamine (designed with red X or Y).  Green squares represent the 
highly sulfated region within the polysaccharide chain, whereas green circles are those 
undersulfation. Image modified from (Sasisekharan et al. 2002) © Nature Rev. Cancer (2002) Nature 
Publishing Group 
 
HSPGs comprise a highly diverse group of molecules that can be divided in three main 
subfamilies: 1) the membrane-spanning proteoglycans (syndecans, betaglycans and 
CD44v3), 2) the glycophosphatidylinositol (GPI)-linked proteoglycans (glypicans) and 3) 
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the secreted extracellular matrix (ECM) proteoglycans (agrin, collagen XVIII and perlecan) 
(WuYang et al. 2011; Bishop et al. 2007). Cell surface HSPGs function as co-receptors for 
HS-binding ligands, serving as a scaffold that localizes the ligands to the cell surface, 
enabling their interaction with their respective signalling receptors (Bartlett & Park 2011). 
Indeed, HS normally binds to a wide variety of growth factors, chemokines, enzymes and 
matrix components and regulates numerous cell physiological processes such as metabolism, 
transport, information transfer, support and regulation at the systemic level as well as at the 
cellular level (WuYang et al. 2011; Bishop et al. 2007). It has been demonstrated that HSPGs 
can also function as primary receptors mediating the endocytosis of polycationic 
macromolecules and cationic peptides via macropinocytosis, clathrin-dependent or -
independent endocytosis (Poon & Gari 2007) (Christianson & Belting 2014). Despite the 
physiological roles of HSPGs, they can also contribute, under certain conditions, to the 
development of pathological status, as in the case of cancer, facilitating primary tumour 
growth and modulating the process of angiogenesis (Sasisekharan et al. 2002). Moreover, 
HSPGs can serve as attachment factors for a wide number of pathogens including bacteria, 
protozoa as well as several viruses belonging to different families (Bernfield et al. 1999). As 
it is shown in Table 1,  cellular HS is known to be used as attachment receptor for DNA as 
well as RNA virus families (WuYang et al. 2011).  In viral pathogenesis, HSPGs are 
commonly exploited by multiple viruses (HS-binding viruses) as low affinity co-receptors 
that entrap and concentrate particles on host cell surfaces facilitating the following binding 
to receptors with a higher affinity. Such attachment strategy allows the pathogen to reach 
the cognate secondary receptor, even if it is expressed at low numbers on the cell surface 
(Spillmann 2001). 
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Table 1.  List of viruses that use heparan sulfates as attachment factor. Adapted from 
(WuYang et al. 2011) 
 
 
 
 
 
 
 
 
 
 
 
 
Many human pathogenic viruses have been identified as HS-binding (Liu & Thorp 2002), 
for example Herpes simplex virus type 1 and 2 (HSV-1 and 2) (Cheshenko et al. 2007), 
Human papillomavirus (HPV)  (Shafti-keramat et al. 2003), Human immunodeficiency virus 
type 1 (HIV-1) (Connell & Lortat-Jacob 2013), Dengue virus (DENV) (Hilgard & Stockert 
2000). Historically, HSV-1 was the first viral pathogen that has been reported to use HS as 
attachment  receptor. The interaction with HS carrying a specific sulfonation pattern allows 
both HSV-1 attachment and penetration through specific binding sites of HSV glycoproteins. 
Interestingly, it has been found that the addition of HS or its drug mimetic heparin inhibits 
viral attachment and entry into cultured cells after treatment. This mechanism can be due to 
direct competition with cellular HS and/or other GAG receptors (Guibinga et al. 2002). 
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1.3 Virus entry into the cell !
The transfer of the viral genetic content and accessory proteins into the host cells involves 
two distinct processes: fusion with host membrane, in case of enveloped viruses, or 
endocytosis for non-enveloped viruses (Figure 3). 
 
!
 
Figure 3. Virus entry into cells. 
 (a) Adenovirus virions bind to a primary receptor, the Coxsackie and Adenovirus receptor (CAR) 
and to co-receptors (integrins) on the host cell membrane. This complex triggers various cell 
responses, including clathrin-mediated viral endocytosis. Adenovirus is then delivered to 
intracellular endosomes which acidification (H+) allows the virus to escape in the cytosol. 
Intracellular signalling leads to Adenovirus transport towards the nucleus where it docks to nuclear 
pore complex receptors, disassembles and releases its double stranded DNA (Davidson & 
Breakefield 2003; Meier & Greber 2004). (b) Herpes simplex virus (HSV) virions infect host cells 
through initial attachment between viral envelope glycoproteins and heparan sulphate proteoglycan 
(HSPGs) on the plasma membrane. Virion envelope then fuses with the membrane of the host cell 
and the capsid is released in the cytoplasm and moves by dynein-mediated transport to the nucleus. 
HSV double-stranded DNA can then be transferred into the nucleus through the nuclear pore 
(Choudhary et al. 2011). Image modified from (Davidson & Breakefield 2003) Nat. Rev. 
Neuroscience © Wiley-Liss Inc (1998). 
 
The majority of viruses need internalization via endocytosis in order to infect target cells 
(Marsh & Helenius 2006). This entry strategy is exploited by viruses because it offers several 
advantages. Viruses are driven into the cytoplasm by endocytic vesicles that can traverse the 
barriers consisting of the membrane cortex and the highly structured cytoplasm. A further 
advantage is represented by the fact that incoming viruses are exposed to a mildly acidic pH 
a b
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in endosomes which in turn triggers the virus uncoating (Smith & Helenius 2004; Marsh & 
Helenius 2006). Two main endocytic pathways are frequently used by viruses:  
1.! Clathrin-Mediated Endocytosis. It is a process that enables the uptake of viruses into 
the cytosol from the surface using clathrin-coated vesicles (McMahon & Boucrot 2011). 
Such endocytic route is commonly used by viruses and it is usually rapid and efficient. 
The incoming viruses are transported into endosomes which acidic milieu triggers 
changes in viral conformation leading to endosome escape. Considering the wide range 
of viruses that are known to use clathrin-mediated endocytosis, only those with a 
diameter of approximately 30 nm (e.g. rhinovirus) can fit into clathrin-coated vesicles 
without altering their formation. Viruses having a larger diameter size from 80 to 150 
nm (e.g. reovirus and influenza A) require clathrin-coated vesicles to increase their size 
in order to accommodate the viral particle (McMahon & Boucrot 2011). It has been 
demonstrated that a lot of different cofactors, adaptors, and kinases belonging to many 
different classes are involved in the formation of clathrin-coated pits and vesicles 
(Robinson 2004), thus highlighting the complexity of this endocytic pathway.  
2.! Clathrin-Independent Endocytosis. Some viruses exploit clathrin-independent 
endocytosis mechanisms for cell entry. An example is SV40 virus that uses the 
caveolar/rafts pathways, specialized in the internalization of lipids including cholesterol, 
GPI-anchored proteins, and components of cholesterol rich microdomains (lipid rafts) 
(Anderson et al. 1996). The capsids of SV40 and the related polyomavirus are composed 
of 72 homopentameric VP1 protein units that resemble cholera toxin B chain pentamers 
(Stehle et al. 1996). These viruses bind to the sugar moiety of gangliosides and enter 
cells via caveolar/raft pathways that are dependent on cholesterol and the activation of 
tyrosine- kinase signalling cascades (Tsai et al. 2003; Pelkmans et al. 2001; Smith et al. 
2003). Two steps are involved in the caveolar/raft pathway: initially, viruses are 
delivered to pH-neutral caveosomes and then they are transported via microtubules, to 
the endoplasmic reticulum (ER) where penetration occurs (Pelkmans et al. 2001). Other 
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viruses that use caveolar/raft endocytosis include Echovirus 1 (EV1), a picornavirus that 
binds to integrins, and Coxsackie virus B (CVB) that infects human Caco-2 epithelial 
cells (Pietiäinen et al. 2005).  
Moreover, although the majority of viruses can infect cells exploiting the endocytic 
mechanisms, some viruses belonging to different families (such as vaccinia, adeno, picorna) 
can take advantage of an alternative internalization mechanism known as macropinocytosis 
(Mercer & Helenius 2009). Macropinocytosis is a transient actin-dependent endocytic 
process that leads to internalization of fluids and membranes into large vacuoles. Indeed, 
virus particles can activate signalling pathways that trigger cytoskeletal rearrangements in 
the form of membrane ruffling or blebbing, with the subsequent formation of large vacuoles 
(macropinosomes) that allows the internalization and penetration of viruses into the cytosol 
of the cell (Mercer & Helenius 2009). Several recent studies have reported that this kind of 
endocytic route is used by many viruses such as Vaccinia virus, Adenovirus type 3 (Ad3) , 
EV1, CVB and Ebola virus (Mercer & Helenius 2008; Meier et al. 2002; Liberali et al. 2008; 
Coyne et al. 2007; Saeed et al. 2010). Indeed, mature vaccinia virions are able to enter the 
cell through macropinocytic mechanisms mimicking the uptake of apoptotic bodies. As 
demonstrated by Mercer et al., addition of mature vaccinia virions to cells leads to an 
increased uptake of fluids and the internalized particles co-localize with fluid phase markers 
(Mercer & Helenius 2008; Huang et al. 2008). The association of mature virions with cells 
induces the formation of plasma membrane blebs, which are apoptotic bodies rapidly filled 
up with actin and actin-associated proteins. The consequent retraction of blebs allows the 
internalization of adjacent virions along with fluids. Similarly, Ad3, a non-enveloped double 
stranded DNA virus, can activate Rac1-mediated macropinocytosis after binding to its 
cellular receptor (CD46). Adenovirus is found in large, uncoated vacuoles and its 
internalization coincides with enhanced fluid uptake as observed by electron microscopy 
study (Amstutz et al. 2008; Sirena et al. 2004). Moreover, viruses belonging to the 
picornaviridae family like EV1 and CVB make use of macropinocytosis to infect cells. The 
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evidence is given by the fact that virions co-localize with fluid phase markers and both 
require Na+/H+ exchangers and kinases (i.e. PKC, PLC) for a productive entry and thus 
infection (Mercer & Helenius 2008). Virus entry by macropinocytosis is a process still 
incompletely characterized and its relevance remains restricted only to a limited number of 
viruses. It is still unclear how many types of macropinocytosis exist and how many viruses 
can trigger such internalization pathways. Viruses, especially those particles too large for 
clathrin-mediated endocytosis, might have evolved this alternative entry strategy, preferable 
over phagocytosis, to broaden their tropism. Another plausible reason can be the evasion 
from the immune system. In fact, virions internalized within macropinosomes are probably 
not exposed to receptors and other factors that trigger innate immune responses (Mercer & 
Helenius 2008; (Kerr & Teasdale 2009). 
 
1.4 Post-entry events  !
Once viruses have been internalized inside the cell, their capsids are disassembled and viral 
genome as well as viral accessory proteins are released. Many viruses with DNA genome 
release their genetic content into the nucleus in order to start replication and transcription 
whereas RNA viruses, with a few exceptions, start the replication in the cytosol. The 
mechanisms of capsids’ disassemblation (uncoating) are multiple and in some cases viruses 
exploit host cell factors, ribosomes, proteasomes and cytoskeleton motor proteins. For 
example, Adenoviruses exploit dynein, kinesin and nucleoporins in order to open up viral 
capsids that are attached to the Nuclear Pore Complex (NPC) (Pérez-Berná et al. 2012). 
After virus replication and biosynthesis, newly synthesized viral parts are reassembled to 
make infectious virions. The assembly of viral components is a very complex process 
divided in three main phases, that must be tightly regulated: 1) the formation of provirions 
or procapsids, 2) the packaging of viral genome and 3) the maturation of provirions into 
infectious virions (Steven et al. 2005). Usually, infectious progeny of enveloped virus 
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particles leave the cells by budding and secretion, while non-enveloped viruses undergo 
release by cell lysis, even though some may escape by secretory mechanisms after budding 
into membrane bound compartments. In conclusion, post-entry events lead first to the 
disintegration of viruses, with a loss in their bodily integrity, and then to the reconstruction 
of infectious progeny from newly synthesized viral parts. Taken together these processes 
(disintegration and reconstruction) represent the most fundamental aspects in viruses’ life 
cycle and represent a distinctive feature of viruses (Wolkowicz & Schaechter 2008).  
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Chapter 2 !
2.1 Current strategies to fight viruses !
In the era of globalization, characterized by widespread and rapid human movements, viral 
infections are becoming a global health emergency both for developed and poor countries. 
Infectious diseases account for ~20% of global mortality, with viral diseases responsible for 
about one third of these deaths (Lozano et al. 2012). Despite advanced diagnostic tools (e.g. 
genomic sequencing, proteomics, epigenomics) that facilitate detection, identification, and 
control of infections, the ongoing outbreak of Ebola as well as Chikungunya (CHIKV) and 
Dengue virus (DENV)  underlines human vulnerability to viral pathogens. Nowadays three 
main strategies are available to fight viral infections: vaccines that prevent infections, 
antiviral drugs that can treat infectious diseases and virucidal substances that render 
pathogens non-infective before they interact with the host. 
 
 2.1.1 Vaccines !
Conventionally, the most widely used approach for long-term prevention is vaccination that 
has led to the effective eradication and confinement of important viral pathogens. Indeed, 
vaccines are the most powerful tool to prevent viral infections and have accomplished 
remarkable decreases of virus-related diseases wherever applied (Plotkin 2005). Vaccines 
are currently made of suspensions of killed microbes or purified and concentrated 
proteins/polysaccharides from pathogens which stimulate body’s immune system (Plotkin 
2009). Initially, starting from Pasteur’s observations, viruses were attenuated by exposure to 
high temperatures, oxygen and chemicals. In the twentieth century methodological 
breakthrough, such as the attenuation of viruses by their growth in cell culture and complete 
virus inactivation, have led to the development of vaccines against important human viral 
pathogens like poliovirus, measles virus, mumps virus, rubella virus, varicella zoster virus 
(Plotkin & Plotkin 2011) (Plotkin 2005). Deep understanding of the mechanisms of virus-
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host interaction as well as viral structure have improved the rational design of vaccines. 
Furthermore, new strategies exploiting virus-like particles have broadened the field of 
effective vaccination. Moreover, with the advances in molecular biology and genetic 
engineering, it became possible to create inactivated antigens and attenuated pathogens 
through directed mutations in their nucleic acids. Thus live recombinant viruses and bacteria, 
if themselves are not causing illness (apathogenic), may be used as live vaccines (Plotkin 
2005). Indeed, in recent years such viral vectors expressing genes encoding for relevant viral 
proteins as well as virus-like particles and multiprotein structures that mimic native viruses 
but lack viral genes have been tested in preclinical and clinical studies for improved vaccines 
against a plethora of viruses (Roldão et al. 2015). Although passive immunotherapy and 
preventive vaccines are widely diffused, there is an increasing need to develop effective viral 
inhibitors that can interfere with enzymes involved in the late steps of viral replication, hence 
blocking further virus propagation.  
 
2.1.2 Antiviral drugs !
Despite the success of vaccination programs against human pathogens, such as smallpox, 
polio, measles, mumps and rubella, the vaccine approach have so far proved to be ineffective 
with other life-threatening viruses, particularly HIV and Hepatitis C Virus (HCV) (Littler & 
Oberg 2005). Over the last 30 years, research has thus focused on the development of 
antiviral drugs effective in the treatment of infections or debilitating diseases caused by  
three main types of viral pathogens (Littler & Oberg 2005), Table 2. The basic strategies 
used to design antiviral drugs can target either viral proteins or cellular proteins (De Clercq 
2002). Compounds designed to hit viral proteins are more specific, less toxic and with a 
narrow spectrum of antiviral activity but they are prone to virus-drug resistance 
development. On the other hand, antivirals targeting cellular proteins have a broader activity 
spectrum and less chance of resistance development, but higher likelihood of toxicity. The 
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development of antiviral drugs is strictly dependent on the nature of the virus as well as on 
the target type of host cell (De Clercq 2002). 
Table 2. Approved antiviral drugs for human deficiency virus (HIV), hepatitis C virus (HCV), 
herpes simplex virus (HSV) type 1 and type 2. Table adapted from (Szunerits et al. 2015) 
 
 
 
 
 
 
 
 
 
 
 
Being viruses obligate intracellular parasites that depend on the host cell for their replication, 
only a limited number of virus-specific enzymes can be targeted by antiviral drugs without 
harming the host. Moreover, each virus has specific metabolic functions, making the 
development of broad spectrum antiviral drugs difficult (Lembo & Cavalli 2010; Szunerits 
et al. 2015). Antiviral molecules can target viral processes both extracellularly and 
intracellularly and thus block the spread of viral infection. The current antiviral repertoire 
includes two main types of molecules: 
1)! Inhibitors of early events of the infection, like viral adsorption and virus-cell 
fusion. Negatively charged polymers, for example polysulfates, polysulfonates, 
polycarboxylates, polynucleotides, polyoxometalates and negatively charged 
albumin have been shown to inhibit, in in vitro studies, HIV as well as HSV 
replication, by preventing virus attachment to the membrane of target cells.  
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Polyanions exhibit two main important properties: broad spectrum activity and low 
induction of viral resistance in cell culture. However, the activity of polymeric anions 
in vivo is hampered by several drawbacks like short plasma half-life (1-2 hours), 
rapid degradation in the gut and in plasma and poor ability to penetrate and target 
infected tissues and cells. The therapeutic usefulness of polyanions in vivo will be 
far from satisfactory and therefore it has been suggested to be used in combination 
with efficient drug delivery systems in order to exploit their antiviral activity 
(Lüscher-Mattli 2000). Antiviral drugs can act as antagonist of viruses’ co-receptors 
and thus used to block the fusion between the viral envelope and the cellular plasma 
membrane. Several compounds (bicyclam AMD3100 and TAK779) have been 
shown to block HIV entry into the cells as antagonists of the co-receptors CXCR4 
and CCR5 (De Clercq 2015; Dragic et al. 2000). 
2)! Inhibitors of viral intracellular replicative processes. Antiviral molecules can act 
intracellularly, targeting viral enzymes essential in the replicative cycle of viruses, 
such as the viral DNA polymerase, the reverse transcriptase (RT) and viral integrase 
and protease. Nucleoside analogues, like acyclic guanosine analogues (acyclovir, 
penciclovir) or thymidine analogues (brivudin), are used for the treatment of 
herpesvirus infections and target viral DNA polymerase (De Clercq 2002; Szunerits 
et al. 2015). The RT is a key enzyme in the replicative cycle of retroviruses, such as 
HIV, as it synthesizes the proviral DNA, which will then be integrated into the host 
cell genome and passed on to all progeny cells. RT was identified as a suitable target 
for antiviral drugs and several nucleoside and nucleotide analogues acting as 
competitive substrates terminating DNA synthesis have been developed (Littler & 
Oberg 2005). The process of reverse transcription (from RNA to DNA) is inhibited 
by the use of nucleoside reverse transcriptase (NRTIs) and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) acting as competitive substrates/inhibitors of the 
respective natural substrates (dNTPs) at the catalytic site of RT. The mechanism of 
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action of NRTIs, such as zidovudine (azidothymidine, AZT) is depicted in Figure 4. 
 
!
Figure 4. HIV life cycle and targets for anti-HIV agents. 
The five major families of antiretroviral drugs are: 1) adsorption and fusion inhibitors that block 
attachment and entry of HIV virions into the host cell, 2) nucleoside or nucleotide reverse 
transcriptase inhibitiors (NRTIs) and 3) non- nucleoside reverse transcriptase inhibitiors (NNRTIs) 
that block the activity of the reverse transcriptase (RT), 4) integrase inhibitors that block the 
integration of proviral DNA into the host cell DNA, 5) protease inhibitors that interfere with 
assembly of new infectious virions (Mallipeddi & Rohan 2010). Enlarged the antiviral mechanism 
of action of 3’-azido-3’-deoxythymidine (AZT). AZT is dideoxynucleoside analogue able stop the 
replicative cycle of retrovirus, such as HIV, by acting as chain terminator for the reverse transcription 
(RNA→DNA) reaction. It can interact with the RT once has been phosphorylated consecutively 
inside the host cell by cellular kinases in the form of 5’-triphosphate derivative. Images modified 
from (De Clercq, 2002) © Nature Rev. Drug Dicov. (2002) and (De Clercq, 2004) © Nature Review 
Microbiology (2002) Nature Publishing Group. 
 
 2.1.3 Virucidal molecules !
Although immunization, through vaccines, still represent the most effective way to prevent 
viral infections, other preventive measures against pathogens are also available. Approaches 
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that limit the spread of viruses are normally accomplished by the application of disinfectant, 
or virucidal agents, which inactivate viruses on contaminated surfaces or on human hands 
(Ohtake et al. 2010). Indeed, virucides can attack and inactivate the extracellular viral 
particles (virions) by physical contact. Oppositely, to virustatic drugs, virucidal molecules 
act directly and rapidly by either damaging the virion capsid or penetrating into the virion 
and destroying its genome. As a result, the viral particle integrity could be affected and thus 
will be no longer able to infect (Galabrov 2007; Al-jabri et al. 2000). Four main application 
fields of the virucidal agents could be distinguished: 1) disinfectant of the environment, 2) 
sterilization of biological products, 3) antiviral chemotherapy and 4) elimination of viruses 
from food, sanitary products and cosmetics. The recent failures of phase III experimental 
vaccines against HIV highlighted the need of new strategies (e.g. topical formulations of 
virucidal agents) to limit the infections of HIV through sexual contact (Tripathi et al. 2007). 
Consequently, the attention of the researchers have focused on seeking several molecules 
with virucidal activity against HIV-1. Al-Jabri et al. (Al-jabri et al. 2000) observed virucidal 
activity of four synthesized tyrosine-conjugate bile salt derivatives (di-iodo-
deoxycholytyrosine (DIDCT), di-iodo-chenodeoxycholyltyrosine (DICDCT), di-iodo-
cholylglycyltyrosine (DICGT) and deoxycholyltyrosine (DCT)) against three different 
laboratory-adapted strains of HIV-1 (RF, IIIB and MN) at nanomolar concentrations. 
Furthermore, other substances like monopercitric acid (MPCA) or chlorcyclizine and 
ciprofloxacin HCl were found to have virucidal activity against vaccinia virus and HIV 
respectively (Wutzler & Sauerbrei 2004; Chakrabarty et al. 2000). The main issue regarding 
the clinical application of virucidal agents is toxicity to human tissues. Virucides can be 
severely toxic to cells and tissue and hence cannot be used. Thus, the development of non-
toxic and effective virucidal agents are needed to prevent the spread of infectious diseases 
through human contact with contaminated surfaces. 
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Chapter 3 !
3.1 Nanotechnology and its healthcare applications !
Nanotechnology by definition is the “intentional design, characterization, production and 
application of materials, structures, devices, and systems by controlling their size and shape 
in the nanoscale range (1-100 nm)” (Kim et al. 2010). Given the nanoscopic dimension of 
nanomaterials, they can interact with biological molecules and systems with a resultant 
usefulness for medical applications. The most commonly nanostructured materials 
employed in medicine and approved by the Food and Drug Administration (FDA) or in 
clinical trials, are depicted in Figure 5.  
 
 
 
 
 
 
 
 
 
 
Figure 5. Nanomaterials used for biomedical application and list of nanomaterials in clinical 
use.  
Materials in the nanometer range (1-100 nm) are extensively studied for their application in clinics. 
Some have already been approved by Food and Drug Administration (FDA) while some others are 
in the proof-of-concept stage in research laboratories. Image modified from (Kim et al. 2010)  © N. 
Engl. J. Med. (2010) Massachusetts Medical Society 
 
The main advantages of nanomaterials, compared to atoms or macroscopic materials, is 
given by their high ratio of surface area to volume as well as their ability to be engineered 
and have different sizes, shapes and chemical compositions. These properties allowed 
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nanoscale materials to be used for different application within the field of healthcare 
(Wagner et al. 2006) (Kim et al. 2010). Nanostructured materials are used as drug delivery 
vehicles and can improve the bioavailability and pharmacokinetics of approved drug 
molecule. In case of organic nanomaterials, their hollow or porous core allows the loading 
of numerous therapeutic agents within a single carrier particle. The use of such nano-carriers 
enable to finely control their rate of degradation and the consequent release of the therapeutic 
agents (e.g. antineoplastic drugs). Moreover, nanomaterials can extravasate from blood and 
accumulate into tumours tissues when tumour vasculature has pores smaller than 200 nm 
(Hobbs et al. 1998). Nano-carriers can be coated with several polymers, such as polyethylene 
glycol, which improve their half-life in the blood circulation, prevent the recognition to the 
immune system and reduce their rapid metabolism and clearance. The controlled release of 
drugs with nano-carriers ensure their therapeutic action in localized sites thus minimizing 
adverse effects in healthy tissues (Prencipe et al. 2009; Alexis et al. 2008). Another important 
application of nanomaterials in for in vivo imaging. Indeed, NPs are used as sensitive 
contrast agents, particularly for magnetic resonance imaging (MRI) and ultrasound, for 
cancer imaging. The use of superparamagnetic iron oxide nanoparticles (SPIONs) in MRI 
allows to easily discriminate between tissue with NPs and those without, exploiting their 
difference in the precession frequency of the proton. SPIONs, used in association with 
dextran, can detect possible lymph node metastases in prostate cancer owing to their ability 
to cross the lymphatic vessels and be taken up by macrophages within lymph nodes. 
Compared to a conventional MRI, the injection of SPIONs increases the diagnostic 
sensitivity (90.5% vs 35.4%) and specificity (97.9% vs 90.4%) in the detection of tumors far 
from its primary site (Harisinghani et al. 2007). A key application of nanomaterials 
(nanotubes, nanowires) is their use as novel sensors for diagnostics. Such enhanced sensors 
can improve the sensitivity, simplify the readout or amplify the detection threshold of 
diagnostic devices (Kim et al. 2010). Gold nanoparticles (Au-NPs) bound to the antibody 
that recognizes the human chorionic gonadotropin (anti-hCG)  are used in lateral-flow in 
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vitro diagnostic assay (LFA) as a sensitive detection tool in the urine pregnancy test 
(Posthuma-Trumpie et al. 2009). Moreover, Au-NPs are also used to detect genetic 
mutations in high-throughput genomic detection devices without the need for polymerase-
chain-reaction (PCR) amplification. This approach circumvents the problems associated 
with conventional fluorescent probes for microarray (photobleaching) and enable the 
detection of  multiple markers with 95% sensitivity having a detection threshold of 10-18 M 
(Nam et al. 2003) (Kim et al. 2010).  
Furthermore, mechanical properties and biocompatibility of medical implants can be 
improved by the use of nanomaterials. Examples include nano-hydroxyapatite (HA) that is 
used for hard tissue regeneration, especially for orthopaedic and dental application. 
Nanosized hydroxyapatite particles (< 100 nm), compared to the synthetic HA, are more 
similar to the natural crystalline structure of HA found in bones. This key feature allows 
improved cell proliferation due to better cellular adherence with the host cells (Zakaria et al. 
2013). 
Within this context, among all the nanomaterials designed for clinical applications  
(liposomes, dendrimers, quantum dots, carbon nanotubes) NPs have gained a lot of attention 
in pharmaceutical research and development (R&D) for their wide range of applications 
ranging from drug delivery systems to imaging agents (De Jong & Borm 2008). 
 
3.2 Nanomaterials used as antivirals !
Nanomaterials have shown to be a powerful tool for the development of potential and 
effective pharmaceutics. The possibility to modify objects at the nanoscale level with 
enhanced physicochemical properties allow the application of nanomaterials in the field of 
virology as promising tools for the treatment of viral infections. In particular, nanomaterials 
can be used in two different ways to fight viral infections:  
1.! Nanomaterials as drug nanocarriers, able to deliver antiviral drugs/molecules 
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currently on the market improving their physicochemical parameters (bioavailability, 
drug solubility and pharmacokinetics) (Lembo & Cavalli 2010). Considering nano-
delivery systems used in antiviral therapies, they can be divided into six main groups, 
according to their size and structural composition: 
1.1 Liposomes. Liposomes are lipidic vesicles that contain an aqueous volume. Their 
size ranges from a minimum of 20 nm up to microns. Liposomes are used to deliver 
either hydrophilic drugs, entrapped within their inner aqueous space, or hydrophobic 
drugs, within the lipid membranes (Lembo & Cavalli 2010). Liposomes preparations, 
made of various phospholipid compositions, have been characterized as delivery 
systems of acyclovir drug against genital herpes. They have been incorporated in 
hydrogels prepared from Carbopol resins that conferred excellent bioadhesive 
properties and represented a vehicle suitable for vaginal self-administration. In vitro 
release studies revealed that, in this formulation, liposomes incorporated in the 
hydrogel are applicable as delivery system with a resulting localized and sustained 
release of encapsulated acyclovir (Filipovic et al. 2005).  
1.2 Micelles. Colloidal structures such as polymeric micelles have been used to 
enhance the effective delivery of antiretroviral drugs for HIV. Polymeric micelles 
prepared with block copolymers of poly(ethylene)oxide-polypropylene oxide 
(PEO/PPO), also known as Pluronics (such as P85), can inhibit the efflux transporters 
which are responsible for the low bioavailability on CNS permeability of several 
antiretroviral drugs. Permeability of zidovudine, nelfinavir and lamivudine is 
enhanced when co-administered with P85 in bovine brain microvessel endothelial 
cells and macrophages in in vitro models (Mallipeddi & Rohan 2010; Hädicke & 
Blume 2013). 
1.3 Microspheres. Microspheres, small spherical particles with diameters in the 
micrometer range, have been used as drug delivery systems for antiviral drugs. Those 
manufactured from synthetic materials, like polymeric nanospheres, have been used 
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as gastroretentive delivery system to improve the oral bioavailability of acyclovir or 
as a topical formulations to increase the local concentration of acyclovir in the HSV 
site of infection (Dhaliwal et al. 2008; de Jalón et al. 2001). 
1.4 Dendrimers. Dendrimers are a class of well-defined hyperbranched polymers 
with unique properties, such as nanoscale globular shape, well-defined functional 
groups at the periphery, hydrophobic and hydrophilic cavities. These properties, in 
particular the highly regular branching pattern and the well defined numbers of 
exposed functional groups, make them attractive for the binding of drugs, including 
antivirals, and thus as effective nanocarriers. Acyclovir-thiophosphate dendrimer 
conjugates have been produced and could be used as water-soluble macromolecular 
prodrugs (Salamon 2003).  
1.5 Hydrogels. Antiviral drugs can be incorporated into copolymers hydrogels. 
Efavirens, a non-nucleoside reverse transcriptase inhibitor (NNRTI) with low 
aqueous solubility, has been incorporated into polyethylene oxide/polypropylene 
oxide block copolymer hydrogels for the treatment of HIV in children (Malmsten 
2011). 
1.6 Nanoparticles. Polymeric nanoparticles, such as polyhexycyanacrylate 
nanoparticles, have been proposed as carriers of antiviral agents for HIV infections 
in vitro. Particles loaded with either the protease inhibitor saquinavir (Ro 31-8959) 
or the nucleoside analogue zalcitabine (2’,3’ –dideoxycytidine) have been tested for 
their antiviral activity in primary human monocytes/macrophages. Saquinavir loaded 
NPs have been found to be ten times more effective than the drug itself in aqueous 
solution (1 nM vs 10 nM) (Bender et al. 1996). Similarly, metal NPs like Au-NPs 
have been tested as an efficient delivery system for small interfering RNAs (siRNAs) 
against Dengue virus (DENV) infections (Paul et al. 2014). In vitro studies showed 
that anti-DENV siRNAs complexed with cationic Au-NPs enter Vero cells and 
reduce the replication and the release of infectious virions of DENV serotype 2 
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(DENV-2). The antiviral ability AuNP-siRNA complexes was exerted both in pre- 
and post-infection conditions. Moreover, siRNAs complexed with NPs could still 
inhibit DENV-2 when incubated with RNase, demonstrating that in such formulation 
siRNAs were less vulnerable to degradation. These findings along with the lack of 
anti-DENV drugs or vaccines highlight the importance of this nanoparticles delivery 
system as potential novel anti-DENV strategy cooley (Paul et al. 2014). 
2.! Nanomaterials as active antiviral compounds. Nanomaterials can themselves  interact 
with viral particles and block the infectious cycle at its very early stages (Lembo & 
Cavalli 2010). Additionally to their ability to deliver antiviral drugs, nanomaterials can 
be exploited as antiviral molecules due to their unique features, such as size as well their 
versatile functionalization properties. In particular, metal nanoparticles, such as gold 
nanoparticles (Au-NPs) or silver nanoparticles (Ag-NPs) are emerging as promising 
nanopharmaceutical drugs respect to conventional antiviral molecules. Indeed, 
considering their small size and, consequently, their high surface area, NPs can engage 
multivalent interactions with infectious virions and thus interfere with early events of the 
infection. Regarding Ag-NPs, several recent studies have reported their potential 
application as antivirals. Elechiguerra et al. (Elechiguerra et al. 2005) described the use 
of Ag-NPs with three different capping agent molecules (foamy carbon, poly N-vinyl-2-
pyrrolidone (PVP) and bovine serum albumin (BSA)) as anti-HIV agents. Ag-NPs were 
found to inhibit HIV-1 at non-toxic concentrations by in vitro assays in a dose-dependent 
manner. Moreover, through the aid of high angle annular dark field (HAADF) scanning 
transmission electron microscopy (STEM), they determined that Ag-NPs, within the 
range of 1-10 nm, were not randomly attached to the virus but they established spatial 
relationship with the HIV-1 envelope. The Ag-NPs were found to interact with gp120 
glycoprotein knobs which are responsible for the attachment and subsequent infection of 
host cells (Elechiguerra et al. 2005). The mode of action of PVP functionalized Ag-NPs 
against HIV-1 was further elucidated by Lara et al. (Lara et al. 2010). The antiviral 
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activity of Ag-NPs was exerted both extracellularly, by blocking the initial HIV-1 
absorption, particularly the gp120-CD4 interaction, and intracellularly, showing antiviral 
activity at post-entry stages, after the cell had been infected. Silver ions could bind RNA 
or DNA molecules and thus reduce the reverse or proviral transcription rates. In another 
study, the inhibitory ability of coated Ag-NPs was evaluated with Respiratory Syncityal 
Virus (RSV) (Sun et al. 2008). Nanoparticles, capped with various proteins (PVP, BSA 
or recombinant F protein from RSV (RF 412)), were analysed by different techniques 
for their ability to bind to RSV virions. Transmission electron microscopy (TEM) studies 
revealed that only PVP-coated Ag-NPs could bind to the viral surface with a regular 
arrangement, whereas BSA or RF 412-conjugated NPs seemed to interact with RSV, but 
without a specific association or spatial arrangement. The small size (4-8 nm) and 
uniformity of PVP-coated NPs, compared to the other two functionalized NPs, lead to 
hypothesize that they could interact with the RSV envelope glycoproteins (G proteins) 
which serve as receptor binding protein. These findings along with infectivity assays, 
which showed that only PVP-coated NPs could inhibit RSV infection, allowed to 
conclude that Ag-NPs conjugated with PVP protein could bind to RSV glycoproteins 
involved in the binding to the receptor, thus interfering with viral attachment to the host 
cell (HepG2) and resulting in the inhibition of viral infection. Other similar studies 
pointed out the role of NPs coated with different molecules as potential inhibitors of 
diverse pathogenic viruses. Baram-Pinto et al. described the use of both silver and gold 
functionalized NPs as useful tools against HPV and HSV-1 (Baram-Pinto et al. 2010; 
Baram-Pinto et al. 2009). The capping molecule chosen for both the metal particles was 
mercaptoethane sulfonate (MES) which was intended to mimic HS, the virus binding 
sites on the cells. Their results indicated that both Ag-MES and Au-MES nanoparticles, 
but not the soluble MES molecule, could inhibit HSV-1 infection by blocking the 
attachment and thereby the entrance of the virus into the cell and/or by preventing the 
cell-to-cell spread of the virus. The use of Au-NPs as antivirals has also been explored 
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by Papp et al. (Papp et al. 2010). They demonstrated that Au-NPs capped with sialic acid 
(SA)-terminated glycerol dendron could successfully inhibit the binding of the influenza 
virus to the plasma membrane. In their study they found that only 14 nm, and not 2 nm, 
NPs were able to effectively inhibit viral infection in both hemagglutination and 
inhibition assays. Differently from the aforementioned studies, nanoparticles can exert 
their antiviral ability by enhancing the immunogenicity against the pathogen without 
interacting with virions. One interesting application of these new technologies has been 
used in the treatment of influenza. Scientists created nanoparticles fully covered with 
hemagglutinin, the attachment protein exploited by H1N1 virus, in order to induce 
elevated immune responses and counteract its high mutation rate and its ability to 
efficiently evade efficiently host immune system (Kanekiyo et al. 2013). 
 
3.3 Nanomaterials used as virucidal agents !
Among the wide range of nanotechnological applications in the field of virology, like drug 
carrier or antivirals, an emerging field of research explores the use of nanomaterials as 
virucidal agents. In particular, the use of nanosystems to inactivate infectious particles may 
be advantageous compared to physical and chemical inactivation approaches, and may 
significantly contribute to the prevention of viral infection. Lara et al. have suggested that 
Ag-NPs exert anti-HIV activity binding to viral gp120 glycoprotein and thus acting as 
virucidal agent, inactivating the HIV-1 after a short exposure of infectious viruses to Ag-
NPs, or as inhibitors of viral entry (Lara et al. 2010). Virucidal activity against cell-free HIV-
1 was also observed by Bastian A. R. with the use of modified peptide triazole inhibitor 
(KR13) alone or conjugated to Au-NPs (Bastian et al. 2011). Another potential 
nanoparticulate system with virucidal action was the gold/copper sulfide (Au/CuS) NPs. 
Broglie et al. showed that using norovirus GI.1(Norwalk) virus like particles (VLP) as model 
for human norovirus, they could inactivate viruses by degradation and damage of capsid 
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proteins (Broglie et al. 2015). Other nanomaterials such as dendrimers or polymeric nano-
micelles were also tested for their virucidal activity. The former, SLP7013 dendrimer, 
formulated in a mucoadhesive carbopol gel (VivaGel) was tested as topical microbicides. 
Telwette and co-workers found that SPL7013 dendrimer had potent virucidal activity against 
certain strains of HIV-1 (X4 and R5X4) . 
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Chapter 4 !
4.1 Sulfonated NPs as broad spectrum agents for HS-binding viruses !
Current advances in nanotechnology opened new frontiers in developing novel antivirals 
that can interact and inactivate a large number of viral pathogens. Indeed, as demonstrated 
by several recent studies (Papp et al. 2010; Baram-Pinto et al. 2010), functionalized NPs can 
be coated on their surface with ligands (molecules) that hinder initial virus-cell interactions, 
in particular the binding to permissive cells. Molecules bound to the surface of NPs can 
expose their functional groups mimicking the natural virus receptor and competing for its 
binding to the cell. Within this context, an attractive strategy to block the adsorption of 
viruses on cells is using sulfonates as NPs’ capping ligands, owing to their potential antiviral 
activity against the whole subset of viruses specifically binding sulfates on cells (HS-binding 
viruses). To address this issue, in the present study we investigated the ability of Au-NPs 
exposing different amounts of sulfonated molecules as antiviral agents. Two types of 
sulfonated NPs have been selected on the basis of the different ligands arrangements on their 
surfaces: nanoparticles homogeneously coated by a homoligand shell of 11-mercapto- 1-
undecanesulphonates (MUS), called MUS NPs, and nanoparticles that are instead composed 
by a striated shell of a longer hydrophilic (MUS) and a shorter hydrophobic (1- octanethiol, 
OT) ligand regularly arranged in ribbon-like domains on the surface, called MUS:OT NPs 
(Jackson et al. 2004; Uzun et al. 2008). These sulfonated NPs were used in previous 
experiments for their ability to penetrate cell membrane and were further characterized for 
their low toxicity in in vitro studies. Verma et al. found that NPs coated with amphipathic 
ligands (MUS:OT) organized in striped domains on their surfaces were able to cross the cell 
membrane spontaneously, via energy-independent mechanisms, without creating pores and 
causing damage. In the same study, they demonstrate that NPs functionalized with similar 
molecules randomly arranged on the surface, unlike MUS:OT, were up taken by 
conventional endocytic energy-dependent pathways (Verma et al. 2008). Given the low 
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toxicity profile of MUS:OT NPs as well as their unique biological properties, these NPs were 
selected as potential antivirals. The use of sulfonate engineered NPs, able to interact with 
viruses dependent on HSPGs binding, would be a promising strategy compared to the 
common antiviral strategies for three main reasons. First, the site of action will be 
extracellular and so more accessible than usual intracellular targets. Second, this approach 
is not virus specific and therefore could be able to prevent the infection of a wide spectrum 
of viruses. Third, its efficacy will not be challenged by virus mutations that are the main 
reason for the development of antiviral drug resistances. Previous attempts proposed sulfated 
polysaccharides and other negatively charged molecules as competitive antagonists of virus 
attachment to cells (Lembo et al. 2008; Rupp et al. 2007; Ghosh et al. 2008). However, 
despite the large number of studies demonstrating their efficacy in preclinical models, 
sulfated polysaccharides failed in clinical trials (Pirrone et al. 2011). Compared to the 
aforementioned molecules, sulfonate engineered nanoparticles offer additional advantages, 
above all a high local concentration of spatially oriented sulfonate residues, chemically 
bound to NPs and mimicking HSPG host cell surface.  
 
4.2 Viruses used for the experiments 
 
In this study, we assessed the role of sulfate presenting NPs with several viruses: 
1.! Herpes simplex virus type 1 and 2 (HSV-1, HSV-2). HSV-1 and HSV-2 belong to 
the family of Herpesviridae, enveloped DNA viruses. HSV-1 is a common human 
viral pathogen infecting 70-90% of the world population. Viruses of this subfamily 
establish lifelong infections by entering a non-replicating latent state, thus avoiding 
host immune response (Nicoll et al. 2012). Primary infection with HSV, as well as 
reactivation, are associated with oral (HSV-1) and genital (HSV-2) lesions, ocular 
diseases, and in rare cases encephalitis (Hadigal & Shukla 2013). The HSV complex 
structure is composed of a highly ordered protein-shell capsid which encloses the 
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double-stranded linear DNA (McGeoch et al. 2006). The capsid is surrounded by a 
layer containing more than twenty different viral and host proteins. A host-derived 
membrane envelope, with about a dozen viral glycoproteins embedded in the lipid 
bilayer, forms the outer boundary of the viral particle. Five of these glycoproteins 
(gB, gC, gD, and the complex of gH and gL) mediate the entry of HSV-1 into the 
host cells (Subramanian & Geraghty 2007). HSV-1 primary attachment proteins (gB 
or gC) interact with the host cell by binding to HSPGs (Choudhary et al. 2011). The 
subsequent step is entry into the cell, which involves binding to a specific entry 
receptor and is cell-type dependent. Neurons and Vero cells are infected by direct 
fusion at the plasma membrane and release of the capsid into the cytosol, while in 
keratinocytes and HeLa cells entry involves different forms of endocytosis (Karasneh 
& Shukla 2011). A broad spectrum of entry receptors, along with a variety of entry 
mechanisms, enable HSV-1 to infect almost all cell types (including lymphocytes, 
epithelial cells, fibroblasts, and neurons). 
2.! Human papilloma virus (HPV). HPV is one of the most common causes of sexually 
transmitted diseases in both men and women around the world, with prevalence rates 
varying with the studied population and geographical localization (de Sanjosé et al. 
2007). Most HPV infections are transient, and some studies show that the majority 
of sexually active individuals are exposed to and acquire infection from this virus at 
some phase in their life (Baseman & Koutsky 2005). HPVs can generally be divided 
into two tropism groups: those that infect the keratinized surface of the skin, causing 
common warts, and those that infect the mucosa of the mouth, throat, respiratory 
tract, and especially the anogenital tract (Burd 2003; Mistry et al. 2008). Today, more 
than 120 different HPV types have been catalogued, and about 40 can infect the 
epithelial cells of the anogenital tract and other mucosal areas of the human body 
(Bernard et al. 2010). Those viruses are classified according to their involvement in 
the genesis of benign or malignant lesions: 1) low-risk oncogenic HPV (LR-HPV) 
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are those associated with anogenital warts, which are benign, hyperproliferative 
lesions with a very limited tendency for malignant progression, mostly caused by 
HPV 6 and 11, 2) high-risk oncogenic HPV (HR-HPV) that are strongly associated 
with premalignant and malignant cervical lesions, especially caused by HPV 16 and 
18 (Bosch et al. 2008; de Villiers et al. 2004). Persistent infection with HR-HPV is 
unequivocally established as necessary for the onset of cervical cancer (Bosch et al. 
2002).  HPV is a non-enveloped virus that contains a double-stranded, closed circular 
DNA genome, associated with histone-like proteins and protected by a capsid with 
icosahedron symmetry, formed by two protein types. Each capsid is composed of 72 
capsomeres, each of which is composed of five monomeric units that join to form a 
pentamer corresponding to the major protein capsid (L1). The L1 pentamers are 
distributed forming a network of intra- and interpentameric disulfide interactions, 
which stabilize the capsid (Sapp et al. 1995). L2 protein is the secondary component 
of viral capsid and is located within the virion. 
3.! Lentiviral vectors (LV). Lentiviral vectors, derived from HIV, were created as 
efficient vehicles for gene transfer owing to their ability to infect dividing and non-
dividing cells. The first lentiviral gene delivery system was described by Naldini et 
al. (Naldini L. et al. 1996) in 1996 consisting in the use of a replication-incompetent 
HIV vector capable of transducing non-dividing neurons when injected into rat 
brains. Lentiviral vector production requires the co-transfection of  several plasmids 
expressing lentiviral structural and enzymatic proteins along with “a vector plasmid” 
carrying the genetic cargo of interest into Human Embryonic Kidney (HEK) 293T 
cells (Peltier & Schaffer 2010). First and second-generation of lentiviral vectors were 
constituted by three different plasmids while third-generation vectors are based on 
four plasmids. Use of  lentiviral vectors systems is particularly desirable given their 
extraordinary ability to accommodate heterologous envelope proteins and thus 
acquire novel cellular tropism and intracellular behaviour (Durand & Cimarelli 
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2011). Incorporation of different proteins, called pseudotyping, is a process common 
to  all retroviruses and allows to engineer viral particles with envelope proteins, such 
as the vesicular stomatitis G protein (VSV-G), that mediate viral entry into a wide 
variety of cells. Similarly, lentiviral vectors can be pseudotyped with envelope 
proteins (gp160) that specifically target cellular receptors (CD4) expressed on the 
selected cell type (e.g. lymphocytes). These features allowed lentiviral vectors to 
become an important laboratory tool for the transduction of cell types resistant to 
gene transfer (e.g dendritic cells and neurons) as well as for their use as safe and non-
pathogenic replicas of HIV for the study of HIV biology, (tropism, penetration, 
genome integration) (Anon 2006). 
4.! Adeno associated viruses (AAVs). AAVs, non-eveloped DNA viruses (25 nm), 
belong to the family of Parvoviridae and are able to infect and replicate into a wide 
range of human and nonhuman cells, in presence of a helper virus (Adenovirus or 
herpesvirus). To date twelve human serotypes of AAVs (AAV1 to AAV12) and 
hundreds from nonhuman primates have been discovered (Daya & Berns 2008).  
AAVs possess key features such as, lack of pathogenicity, wide range of infectivity, 
ability to establish long-term transgene expression and site-specific 
integration/episomal maintenance (Wu et al. 2006), features that make them suitable 
for gene therapy applications. Indeed, recombinant AAVs (rAAVs) are frequently 
used as delivery vehicles for gene transfer and are already being used in more than 
20 human clinical trials, as in the case of  AAV microdystrophin gene vectors for 
Duchenne muscular dystrophy (DMD) (Athanasopoulos et al. 2004). The presence 
of several human AAV serotypes, with distinct tropism, allow their selective use 
toward specific types of cells. Serotype two (AAV2) is the most characterized AAV. 
It initially binds to HSPG which act as cell attachment factor and subsequently 
engage interactions with two coreceptors, αv β5 integrin and fibroblast growth factor 
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receptor 1 (FGFR-1) that trigger its endocytic uptake of AAV2 (Büning et al. 2003). 
On the other hand, serotype 5 (AAV5) has a different cell surface attachment 
mechanism and binds alfa 2-3 sialic acid (Kaludov et al. 2001).  
5.! Adenovirus (Ad).  Adenoviruses are non-eveloped, double stranded DNA viruses 
of approximately 90 nm in diameter. Viral DNA and core proteins are enclosed in an 
icosahedral capsid composed of hexon and penton proteins along with elongated 
fiber proteins. Adenoviruses belonging to the species C (Ad2 and Ad5) are widely 
used as genetic transfer vehicles. Adenovirus-based vectors are attractive candidates 
for gene therapy because their genome is well characterized and easy to manipulate 
and they have a broad tropism which allows to infect a wide variety of dividing and 
non dividing cells (Tatsis & Ertl 2004; Zhang & Bergelson 2005; Meier & Greber 
2004). 
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! II. AIM OF THE STUDY 
 
Considering the rapid diffusion of viruses and the limits in contrasting their spread, in the 
present work we have investigated the use of nanoparticles as wide-spectrum antiviral agent.  
To achieve this purpose, we used Au-NPs coated with sulfonate molecules. Our hypothesis 
was that the NPs interfere, through competition mechanism, with the attachment step and 
hence blocking the infectious cycle of whole subset of viruses that attach and recognize 
target cells by binding heparan sulfates as part of the glycocalyx exposed on cell membrane. 
We studied in detail the mechanism of action using as a model virus a replication defective 
virus (LV) as well as wild-type pathogenic viruses, such as HSV-1 and HSV-2. 
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! III. MATERIALS AND METHODS 
 
Materials !
3.1 Synthesis of functionalized Au-NPs  !
NPs were synthesized in-house and consist of an inorganic gold core coated with a self-
assembled monolayer (SAM) of thiolated organic molecules. Two types of monolayer-
protected Au-NPs were investigated for their potential antiviral activity: 
1)! NPs coated with negatively charged sulfonated alkanethiols, 11-mercapto-1-
undecanesulphonate (MUS) alone, referred as MUS NPs 
2)! NPs capped with 2:1 molar mixture of MUS and 1-octanethiol (OT) ligand, referred 
as MUS:OT (66:34) 
In addition, in order to assess the ability of sulfonated NPs to inhibt HSPG-dependent 
viruses, we included in the study gold NPs functionalized with oligo ethylene glycols (EG2-
OH) NPs used as control for non-sulfonated NPs. 
Briefly, for MUS and MUS:OT NPs synthesis, 1.2 mmol of gold salt (HAuCl4) were 
dissolved in 200mL of ethanol and 1.2 mmol of the desired thiol ligand mixture was added 
while stirring the reaction solution. Subsequently, a saturated ethanol solution of sodium 
borohydride (NaBH4) was added dropwise for 2 h. The solution was stirred for 3 h and the 
reaction flask was then placed in a refrigerator overnight. The product was washed several 
times (3 to 5) by suspending and centrifuging (5500 rpm) in methanol, ethanol and then 
acetone. NPs were washed 5 times with deionized water using Amicon Ultra-15 centrifugal 
filter devices (10k NMWL) in order to remove unbound ligands and side products (as 
determined by 1H NMR). Non-sulfonated Au-NPs (EG2-OH NPs) were synthesized in-
house according to a modified Stucky procedure (Zheng & Stucky 2006). The reaction was 
performed in a 100 ml 3-neck round bottom flask in a total volume of 20 ml of a mixture of 
dimethylformamide and 20% Methanol (Sigma Aldrich, Italy), at 100 °C on an oil bath under 
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reflux. Briefly, 0.25 mmol of Chloro(triphenylphosphine)gold(I) (Sigma Aldrich, Italy) and 
0.125 mmol of HS-(CH2)6)-(OCH2CH2)2-OH (ProChimia Surfaces, Poland) were dissolved 
in 15 ml of solvent and then stirred in a 100 ml 3-neck round bottom flask for at least 20 
min. When the reaction temperature is reached, 2.5 mmol of Borane tert-butylmine complex 
previously dissolved in 5ml of solvent were added in one portion to the reaction mixture. 
The solution color turns from transparent to light brown and then slowly to deep red. The 
reaction is left stirring at 100°C for 1h 30’. Afterward, the heating is turned off and the 
solution is left stirring for additional 3h. To recover the nanoparticles, 80 ml of acetone 
(Sigma Aldrich, Milan, Italy) were added to the solution that was placed at 4°C overnight. 
A black precipitate of Au-NPs was suspending and centrifuging at 3220g for 20’ in washed 
acetone. The black precipitate was left to dry under vacuum. Subsequently the black 
precipitate was dissolved in ultrapure deionized water (18.2 MΩ cm at 25°C, Millipore, 
Italy) and dialysed extensively against ultrapure deionized water in a 2L beaker for 72h. 
Removal of residual salts from the synthesis was checked by measuring the conductivity of 
a 0.5 mg/ml solution of nanoparticles, which had to be below 5 µS/cm. The solution obtained 
after the dialysis was then concentrated through diafiltration with Vivaspin 6 ml (Sartorius, 
SIGMA Aldrich, Italy) to a final volume between 1-2 ml. This volume was then lyophilised 
(freeze dried) and the powder recovered (the process decreases the yield to circa 30-35 mg). 
All the NPs were characterized by TEM and zeta potential.  All chemicals were purchased 
from Sigma Aldrich except for the MUS ligand, which was synthesized in-house according 
to the previously published method (Verma et al. 2008). All solvents purchased were reagent 
grade and purged with nitrogen gas for more than 30 minutes prior to the reaction. 
 
3.2 Cell Culture !
HeLa (human cervical carcinoma cell line), HEK293T (human embryonic kidney), Jurkat 
(human T lymphocyte cell line), CHO-K1(Chinese hamster ovary cell line), Vero (African 
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green monkey fibroblastoid kidney cells) and HT-1080 (human fibrosarcoma cell line) were 
purchased from ATCC (American Type Culture Collection, Rockville, MD). HEK293T and 
HT-1080 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Euroclone) 
containing 10% foetal bovine serum (FBS), 1% L-glutamine and 1% 
penicillin/streptomycin. HeLa cells were cultured in Eagle’s minimal essential medium 
(MEM - Invitrogen, Carlsbad, CA) supplemented with 10% FBS SA, 1% L-glutamine and 
1% penicillin/streptomycin (Euroclone). Jurkat cells were maintained in RPMI 1640 
(Euroclone, Carlsbad, CA) supplemented with 10% FBS and 1% L-glutamine and 1% of 
penicillin and streptomycin. CHO-K1 were cultured in Ham’s F12-K medium (Invitrogen) 
supplemented with 10% FBS SA, 1% L-glutamine and 1% penicillin/streptomycin. Vero 
cells, were grown in MEM medium (Gibco/BRL, Gaithersburg, MD) supplemented with 10 
% heat inactivated foetal calf serum (FCS; Gibco- BRL), and 1 % antibiotic-antimycotic 
solution (Zell Shield, Minerva Biolabs GmbH, Berlin, Germany). 293TT cell line, derived 
from human embryonic kidney cells transformed with the simian virus 40 (SV40) large T 
antigen (Buck et al. 2006), was cultured in DMEM (Gibco-BRL, Gaithersburg, MD) 
supplemented with heat-inactivated 10 % foetal calf serum (FCS; Gibco- BRL), Glutamax-
I 1 % (Invitrogen, Carlsbad, CA) and nonessential amino acids 1% (Sigma Aldrich, 
Steinheim, Germany). All cells lines were grown in humidified atmosphere with CO2 (5%) 
at 37°C. HeLa cells expressing human CD4 protein on the cell surface (HeLa T4+) were 
purchased from NIH AIDS reagent program. HeLa T4+ were cultured in DMEM 
(Euroclone) containing 10% foetal bovine serum, 2mM L-glutamine and 1% 
penicillin/streptomycin at 37°C in humidified atmosphere with 5% CO2. 
 
3.3. Viruses !
3.3.1 Lentivirus: production and purification !
Lentiviruses (LV), that are engineered viral vectors obtained from the human 
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immunodeficiency virus (HIV), are the most widely used viral tool for gene delivery due to 
their ability to mediate potent transduction and stable expression into dividing and non-
dividing cells. Lentiviral particles can be manipulated to carry different glycoproteins (GPs) 
derived from other enveloped viruses (pseudotyping) allowing to an extension of the 
tropism. In this study, two pseudotyped lentiviral vectors were produced differing only for 
the expression of their enveloped proteins: LV carrying the G protein of the vesicular 
stomatitis virus (VSV-G) and LV exposing the glycoprotein of HIV (gp160). Production of 
such phenotypically mixed virus particles was accomplished in three steps: 1) calcium 
phosphate transient co-transfection of HEK293T cells with all necessary plasmids , 2) 
concentration of viral vectors using PEG 6000  and 3) purification by ultracentifugation on 
a sucrose cushion (Tiscornia et al. 2006). Generation of infectious lentiviral particles 
required the expression of essential genes in HEK293T cells through several plasmids: 1) 
lentiviral expression plasmid (pRRLSIN.cPTT.PGK-GFP.WPRE), carrying the transgene 
sequence encoding GFP, 2) plasmids encoding packaging proteins (pMDLg/pRRE, pRSV-
Rev), with gag, pol, rev and tat genes and finally 3) pseudotyping plasmid (pMD2.G) 
encoding the envelope glycoprotein of VSV (VSV-G) or plasmid encoding the envelope 
protein of HIV (gp160) . The Env plasmid encoding for gp160 of HxB2 strain of HIV was 
kindly donated by Prof. Didier Trono (Laboratory of virology and genetics at École 
polytechnique fédérale de Lausanne - EPFL). The HIV-Env plasmid was previously 
amplified through transformation of chemically competent E.coli (One Shot®, Invitrogen) 
and then purified using QIAGEN Plasmid Maxi Kit. Lentiviral particles were collected 48 
hours after transfection. LV particles were then concentrated by precipitation using PEG- 
it™ (System Biosciences, SBI) and resuspended in PBS. Concentrated virus was transferred 
in cryo-tubes and stored at -80°C. Subsequently, the titer was calculated as the number of 
functional particles able to deliver their genetic materials in cells (transducing units/ml - 
TU/ml) and determined in HeLa cells using serial dilutions of lentiviral preparation, 
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evaluating the percentage of GFP positive cells by flow cytometry. Lentiviral stocks,  
produced in-house, had titers ranging from ≅ 5x106 TU/ml to ≅ 5x108 TU/ml and were used 
at 105-106 TU/ml in cell experiments. 
In order to obtain lentiviral stocks with higher degree of purity for Western blot and DLS 
experiments, lentiviral particles stored at -80°C were rapidly thawed and further purified 
through ultracentrifugation on 20% (w/v) sucrose cushion. Viral preparations (200 µl) were 
layered on 1.5 ml of 20% sucrose in PBS into ultracentrifuge tubes (Beckman Coulter Inc). 
Subsequently, samples were ultracentrifuged at 19000 rpm for 2h at 20°C using a Beckman 
SW41 (Beckman Coulter Inc) swinging bucket rotor. Finally, the supernatant was discarded 
and the virus pellet was resuspended in 50 µl of PBS. 
 
3.3.2 Adenovirus (Ad) !
Purified human recombinant Adenovirus (Ad) type 5 encoding for green fluorescent protein 
(GFP) was purchased from vector Biolabs (Philadelphia, PA, USA). According to 
manufacturer’s data, Adenovirus was centrifuged using two sequential caesium chloride 
(CsCl) gradients, resuspended in PBS with 5% (w/v) glycerol and stored at -80°C. 
Furthermore, the product was tested for sterility and titrated with UV spectrophotometric 
measurement at 260 nm calculating the number of viral particles (vp/ml) that resulted to be 
5x1010 vp/ml. 
 
3.3.3 Adeno-associated virus (AAV) !
Different serotypes of recombinant Adeno-associated viruses (AAVs) encoding GFP 
(AAV2-GFP, AAV5-GFP) were purchased from Vector Biolabs (Philadelphia, PA, USA). 
According to manufacturer’s data, AAVs were purified through serial gradients of caesium 
chloride (CsCl) and titrated measuring genome particles (GC/ml). AAVs had a titre of 
roughly 1x1013 GC/ml and were stored at -80 °C in PBS with 5% glycerol. 
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3.3.4 Herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) !
Clinical isolates of HSV-1 and HSV-2 were kindly provided by Prof. M. Pistello, (University 
of Pisa, Italy).!HSV-1 and HSV-2 strains were propagated and titrated by plaque assay on 
Vero cells. Virus stocks were maintained frozen at -80 °C. 
 
3.3.5 Human Papilloma pseudovirus (HPV-16 PsV) production  !
Plasmids and 293TT cells used for pseudovirus (PsV) production were kindly provided by 
John Schiller (National Cancer Institute, Bethesda, MD). HPV-16 PsVs were produced 
according to previously described methods (Buck et al. 2005). Briefly, 293TT cells were 
transfected with plasmid expressing the papillomavirus major and minor capsid proteins (L1 
and L2, respectively), together with a reporter plasmid expressing the secreted alkaline 
phosphatase (SEAP), named pYSEAP. Capsids were allowed to mature overnight in cell 
lysate; the clarified supernatant was then loaded on top of a density gradient from 27% to 
33% to 39 % Optiprep (Sigma-Aldrich, St. Louis, MO) at room temperature for 3 h. The 
material was centrifuged at 28000 rpm for 16 h at 4°C in an SW41.1 rotor (Beckman Coulter, 
Inc., Fullerton, CA) and then collected by bottom puncture of the tubes. Fractions were 
inspected for purity in 10% sodium dodecyl sulfate (SDS)–Tris–glycine gels, titrated on 
293TT cells to test for infectivity by SEAP detection, and then pooled and frozen at -80°C 
until needed. The L1 protein content of PsV stocks was determined by comparison with 
bovine serum albumin standards in Coomassie-stained SDS-polyacrylamide gels.µ 
 
3.4 Antiviral drug 3’-azido-3’-deoxythymidine (AZT) !
The antiretroviral drug AZT was purchased from Sigma-Aldrich and stored at – 20°C. It was 
dissolved in water and aliquots were prepared before in vitro experiments.  
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Methods !
3.5 In vitro cell-toxicity assay  !
The toxicity of Au-NPs was examined using propidium iodide (PI, Sigma) flow cytometric 
assay or MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium] assay. Propidium iodide, a fluorescent stain for nucleic acid, 
allows to calculate the amount of dead cells due to its inability to penetrate into live cells. 
Indeed, PI could only penetrate into cells that exhibit compromised plasma membrane and 
intercalates into double stranded DNA. Once the dye is bound to DNA it is excited at 488 
nm and emits at a maximum wavelength of 617 nm. The percentage of viable cells was 
measured following the same experimental conditions as for the NPs/virus interaction study. 
Cells were incubated with different concentrations of NPs (from 0.1 µg/ml to 100 µg/ml – 
0.1 nM to 100 nM) for 48 h at 37°C. After incubation with nanomaterials, cells were 
harvested by trypsin, washed with 1ml PBS supplemented with 1% BSA and the pellet was 
resuspended in 500 µl of PBS. Finally, 2 µl of PI, at the concentration of 50 µg/ml in PBS, 
were added to the samples and incubated for 5 min at RT in the dark. PI fluorescence was 
immediately determined on a FACS CANTOII flow cytometer (Beckton Dickinson, San 
Jose, CA). Unstained cells were used as negative control samples. The results were analysed 
using BD FACSDiva software. For the MTS assay, cell cultures seeded in 96-well plates 
were incubated with different concentrations of NPs or ligand under the same experimental 
conditions as described for the antiviral assays. Cell viability was determined by the 
CellTiter 96 Proliferation Assay Kit (Promega, Madison, WI, USA) according to the 
manufacturer’s instructions. Absorbance was measured using a Microplate Reader (Model 
680, BIORAD) at 490 nm. The effect on cell viability at different concentrations of 
nanoparticles was expressed as percentage of live cells, by comparing the absorbance of 
treated cells with the one of cells incubated with culture medium.  
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3.6 Cell-surface staining  !
The expression of CD4 proteins on the surface of HeLa T4+ cells was determined by 
antibody staining of cell markers and quantified by FACS analysis. Briefly, cells were 
harvested, centrifuged at 3000 rpm for 5 min and washed once with PBS 1% BSA. Pellet 
was incubated for 30 min with PBS 5% BSA, washed with PBS 1% BSA and incubated for 
1 h at RT with mouse APC anti-human CD4 primary antibody (TONBO Biosciences). The 
antibody was kindly donated by Dr. Maria Rescigno (Immunobiology of Dendritic Cells and 
Immunotherapy Laboratory – European Institute of Oncology (IEO), Milan – Italy). The 
APC anti-human CD4 antibody was diluted 1:1000 in PBS 1% BSA. After three washing 
steps with PBS 1% BSA cells were fixed with formaldehyde 2% and incubated for 20 min 
on ice. Finally, cells were washed with PBS 1% BSA, resuspended in PBS and analysed 
measuring the percentage of stained cells (APC+ cells) by flow cytometry. 
 
3.7 Au-NPs preparation for antiviral assay studies !
NPs were dissolved in Milli-Q grade water, sonicated for 20 min at room temperature and 
then filtered with a 0.22 µm filter in order to sterilize and remove precipitates. Before the 
use with cells, an appropriate amount of 10x PBS was added to the NPs solutions in order to 
obtain the final concentration ready to use in 1x PBS. 
 
3.8 Antiviral Assays !
3.8.1 Pseudotyped Lentiviruses (LV-VSV-G, LV-gp160), Adenovirus and AAVs 
inhibition assay.  !
Pseudotyped Lentiviruses or Adenovirus or AAV2/5, carrying GFP as reporter gene, were 
resuspended in PBS and incubated with increasing concentrations of sulfonated or non-
sulfonated NPs, at concentrations from 0.01 µg/ml (0.01 nM, ≅ 109 NPs) to 100 µg/ml (100 
nM, ≅1013 NPs), in PBS for 1h at 37°C prior to cell infection. The mixture of 
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virus/nanoparticles was subsequently added to permissive cells and transduction was 
stopped after 48h. Cells were fixed with 1% p-formaldehyde (PFA), resuspended in PBS 
and analysed. Transduction efficiency, calculated as the % GFP+ cells, of LV-VSV-G and 
Adenovirus was measured by flow cytometry whereas confocal laser scanning microscopy 
was used to for LV-gp160 and AAVs. 
For LV-VSV-G and Adenovirus, inhibition assay was carried out in 12-well plates with 105 
cells. HeLa, Jurkat and HT-1080 cells were used for LV-VSV-G while HeLa cells for 
Adenovirus, using roughly 105 TU/ml of LV-VSV-G or Adenovirus.  
Inhibition assays for LV-gp160 and both serotypes of AAVs (AAV2 and AAV5) were 
performed on µ-Slide 8 well Glass Bottom plates (Ibidi®) with ≅2x104 cells (HeLa T4+  cells 
for LV-gp160 and CHO-K1cells for AAVs) with an equal amount of viruses. The same 
experimental procedure was followed for the inhibition assay of antiretroviral drug (AZT) 
with LV-VSV-G in HeLa cells.  
 
3.8.2 HSV-1, HSV-2 antiviral assay.  !
The antiviral effect of MUS:OT NPs on HSV- 1 and HSV-2 infection was evaluated by a 
plaque reduction assay. Each virus was incubated with increasing concentrations of NPs 
(0.01 µg/ml to 100 µg/ml), for 1h at 37°C and then added to the permissive cell line. 
Following virus adsorption (2h at 37°C), the virus inoculum was removed; cells were washed 
and then overlaid with a medium containing 1.2 % methylcellulose (Sigma). After 24 h 
(HSV-2) or 48 h (HSV-1) post incubation at 37°C, cells were fixed and stained with 0.1 % 
crystal violet in 20 % ethanol and viral plaques were counted. 
 
3.8.3 HPV-16 PsV antiviral assay.  !
HPV-16 PsV was incubated with increasing amount of MUS:OT NPs (0.01 µg/ml to 100 
µg/ml) for 1h at 37°C. PsV-NPs mixture was added to 293TT cells and incubated for 72h. 
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The SEAP content in the supernatant was determined using a Great Escape SEAP 
Chemiluminescence Kit (BD Clontech, Mountain View, CA) as directed by the 
manufacturer. Thirty minutes after the addition of the substrate, samples were read using a 
Wallac 1420 Victor luminometer (PerkinElmer Life and Analytical Sciences, Inc., 
Wellesley, MA). 
 
3.9 Time of addition (TOA) experiments !
In order to determine whether the MUS:OT NPs could exert their antiviral activity before or 
after virus infection, acting as antiviral molecules (such as AZT), a time-of-addition 
experiment was performed on 12-well plates with LV-VSV-G (105 TU/ml) in a final volume 
of 1 ml. Indeed, MUS:OT NPs, from 0.1 µg/ml (0.1 nM, ≅1010 NPs) to 100 µg/ml (100 nM, 
≅1013 NPs), or AZT (used as a control for its mechanism of action as antiviral drug) were 
incubated with HeLa and HT-1080 cells (105 cells/well) at 37°C for long (3h, 2h) or for short 
(30 min, 10 min) times before infection. Cells were then washed with PBS and LV was 
added for 1h at 37°C. After another washing step with PBS to eliminate unpenetrated virus, 
cells were kept at 37°C for 48h and analysed. In parallel, in order to evaluate how long the 
addition of a compound (NPs or AZT) can be postponed before the loss of its antiviral 
activity, NPs or AZT were incubated with cells at different times post infection (0, 10min, 
30min, 1h, 3h). Then, cells were harvested and analysed after 48h at 37°C. NPs or AZT were 
also co-added with LV during the infection in order to evaluate their antiviral role when they 
get in contact with the virus without any previous incubation step. LV untreated, without 
NPs or AZT, was used as a control.  
 
3.10 Virucidal assay  !
The effect of sulfonated MUS:OT NPs upon infection of HSV-2, LV-VSV-G and 
Adenovirus was evaluated by incubating an effective inhibitory concentration of MUS:OT 
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NPs, > 100 µg/ml ( >100 nM, >1013 NPs),  with viruses for 2h at 37°C as previously 
described (Cavalli et al. 2012). After incubation, the residual virus infectivity was 
determined by titration at high dilutions. 
 
3.11 Attachment assay !
Attachment assay was performed on 12-well plates with LV-VSV-G (105 TU/ml) in HT-
1080 permissive cells (105 cells/well). Briefly, pre-chilled HT-1080 cells were transfected 
with Lentivirus and MUS:OT NPs at 100 µg/ml (100 nM, ≅1013 NPs)  for 1h at 4°C. Cells 
were washed with cold PBS for three times in order to eliminate unbound viruses and then 
the temperature was shifted to 37°C for 1h, to allow the bound viruses to get internalized in 
the cells. After three washes in PBS cells were incubated for 48h at 37°C and then analysed 
by flow cytometry for GFP expression. 
 
3.12 Entry assay  !
The role of MUS:OT NPs during the entry phase was evaluated  on 12-well plates  with LV-
VSV-G (105 TU/ml). Permissive HT-1080 cells (105 cells/well) were pre-chilled and 
incubated with LV particles alone for 1h at 4°C. After three washes with cold PBS, cells 
were shifted at 37°C and treated with MUS:OT NPs at 100 µg/ml (100 nM, ≅1013 NPs) for 
1h. Finally, cells were washed with PBS and incubated at for 48h at 37°C analysed by flow 
cytometry for GFP expression. 
 
3.13 Quantification of transduced cells (GFP+) !
3.13.1 FACS analysis !
Cells were harvested by trypsin digestion, washed with PBS and fixed in 1% PFA 
(paraformaldehyde) in PBS for 10 min at room temperature. Approximately 20000 events 
(cells) were analysed per sample and cells with no virus were used as negative control in 
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order to determine the autofluorescence background. Transduced cells were calculated as 
the percentage of GFP+ cells over the total population of cells analysed. The expression of 
the GFP protein on cells transduced with LV-VSV-G or Adenovirus was assessed through 
the BD FACSCalibur™ flow cytometer (BD Biosciences) and data were analysed with BD 
CELLQuest™ software (BD Biosciences). 
 
3.13.2 Confocal Laser Scanning Microscopy (CLSM) !
Transduction efficiency (GFP+ cells) of LV-gp160 and AAVs (AAV2, AAV5), in presence 
or absence of MUS:OT NPs, was visualized by using an inverted confocal laser scanning 
microscope (Leica TCS SP5) equipped with blue (488 nm) excitation laser line. Cells were 
previously fixed in 2% PFA (paraformaldehyde) in PBS for 10 min. 
 
3.14 Western Blot analysis !
Western blot (WB) analysis was performed in order to confirm the expression of the proteins 
exposed on LV particles (VSV-G or gp160). Pseudotyped lentiviral vectors, LV-VSV-G and 
LV-gp160, were boiled for 30 min at 95°C, loaded and run on 4-20% precast polyacrylamide 
gel (Mini-PROTEAN® TGX™, BioRad). Proteins were then transferred onto a nitrocellulose 
membrane (0.45µm pore; Whatman Group). After blocking with 5% skimmed Milk in PBS 
for 2h at room temperature, proteins of interest were detected with specific primary 
antibodies: mouse monoclonal antibodies anti-HIV p24 (abcam®) diluted 1:2000, mouse 
monoclonal antibody anti-VSV-G tag (abcam®) diluted 1:2000 and goat polyclonal antibody 
anti-gp120 (abcam®) diluted 1:500. Primary antibodies were diluted in 5% skimmed Milk 
in PBS and incubated overnight, at 4°C. After three washes in PBST, appropriate HRP 
conjugated secondary antibodies, anti-mouse 1:10000 and anti-goat diluted 1:100000 in 
PBST were added for 40 min at room temperature. Finally, membranes were washed three 
times in PBST and peroxidase activity was detected with a light sensitive film using an ECL 
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Plus kit (Pierce) by mixing equal amounts of reagent 1 with reagent 2. 
 
3.15 Dynamic Light Scattering (DLS) and ζ-potential  !
A Zeta Nanosizer unit (Malvern) was used to perform dynamic light scattering and ζ-
potential measurements, equipped with a laser at 633 nm wavelength. The instrument was 
operating in back scattering mode (BSM) at an angle of 173°.  Measurements were run at 
least 5 min (5 measurements for each sample, 25 runs, 5 seconds each). The measurements 
were performed at 25°C. NPs solution in water and PBS were sonicated 15 minutes at room 
temperature and filtered 3 times with filter having 0.22 µm pore size before measurements. 
High concentration zeta cell kit was used to perform ζ-potential measurements.  The same 
conditions were applied to calculate the particle size distribution of purified lentiviral vectors 
(LV-VSV-G). 
 
3.16 Cryo-Electron Microscopy (cryo-EM) !
Cryo-EM images were acquired at the SUNMIL group at École Polytechnique Fédérale de 
Lausanne (EPFL), Switzerland. Briefly, for cryo-EM imaging samples (3-4 µl) were 
deposited onto Quantifoil grids, blotted and plunge frozen with a Vitrobot and then acquired 
in a Tecnai G2 Spirit BioTWIN microscope (FEI) in low dose mode at 30kx magnification.  
HSV-2 (107 PFU/mL) were incubated for 1.5h at 37°C with MUS:OT NPs (200 µg/ml).  
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! IV. RESULTS !
4.1 Characterization of Au-NPs !
MUS:OT, MUS and EG2-OH NPs were synthesized in-house as described in materials and 
methods. In Table 3 is shown the physical-chemical characterization of Au-NPs having 
different surface functionalization. TEM measurements revealed that MUS:OT and MUS 
NPs had an average size of 4.5 ± 1.0 nm and 4.3 ± 1.3 nm  respectively. The EG2-OH NPs 
size distribution by TEM shows an average core diameter of 6.2 ± 0.8 nm. The 
hydrodynamic diameter of Au-NPs dispersed in water, was measured by DLS. As reported 
in Table 3 the size of NPs is around 8-10 nm. The MUS:OT and MUS NPs show a negative 
charge surface distribution around -30-40 mV, due to the sulfonated groups onto the NPs 
surface. Conversely, the EG2-OH NPs have a ζ-potential close to zero, due to the lack of  
charged group onto the surface. 
 
Table 3. Morphological, physicochemical characterization and schematic representation of 
Au-NPs used in this study. 
 
 
* determined from TEM images. 
TEM Images SizeDistribution
Core Size* 
(nm)
Hydrodynamic 
diameter (nm)
ζ-Potential 
(mV) Representation
MUS:OT 4.5 ± 1.0 9 ± 1.2 -33.1 ± 0.64
MUS 4.3 ± 1.3 8.5 ± 1.5 -38.0 ± 5.3
EG2-OH
6.2 ± 0.8 10 ± 2.0 -8.5 ± 1.2
Au
Au
Au
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4.2 Cytotoxicity Assay !
Since this study was aimed at assessing the inhibitory potential of sulfonated Au-NPs in 
presence of a large variety of viruses, it was essential to determine the cytotoxic effect of 
NPs on all the cell lines used.  Cells were incubated for 48 hours with several concentrations 
of nanoparticles in parallel with untreated samples used as negative controls (Figure 6). Cell 
viability in HeLa, HT-1080, CHO-K1 and Jurkat cell lines was assessed by flow cytometry 
analysis (FACS) performing a PI staining. As it is shown in Figure 6, NPs did not exhibit 
any cytotoxic effect in the range of concentrations tested, from 1 µg/ml up to 100 µg/ml, 
with viability values maintained close to 100%. Regarding Vero cells and 293 TT cells the 
cytotoxic effect of NPs was evaluated by MTS and similar results were obtained (data not 
shown). 
 
!
 
Figure 6. Cytotoxicity of NPs evaluated with PI. 
Cell viability (%) in presence of MUS:OT NPs was tested on different cell lines after 48h incubation. 
(a) The dead cells were stained with PI and quantified by FACS: Jurkat (squares), HeLa (circles), 
HT-1080 (diamonds) and CHOK-1 (triangles). (b) Cell viability (%) after 48h incubation was 
evaluated in presence of EG2-OH (squares) and MUS (circles) NPs in HeLa cells. 
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4.3 Antiviral assays on HSPG-dependent viruses !
The antiviral activity of sulfonate presenting NPs was tested on a subset of viruses that 
recognize cell surface HSPGs as first cell attachment receptors. This inhibition assay 
allowed understanding whether sulfonated NPs were able to diminish the level of transduced 
cells acting as antiviral agents, and also calculating their half maximal inhibitory 
concentration (IC50) in all viral systems tested. 
!
Figure 7.  Schematic representation of the LV-VSV-G inhibition assay. 
Pseudotyped lentivirus encoding for GFP (LV-VSV-G, 106 TU/ml) and sulfonated NPs, at different 
concentrations, were incubated in PBS for 1h at 37°C. Virus/NPs mixture was subsequently delivered 
to HeLa, Jurkat or HT-1080 permissive cells (105 cells/well) for 48h at 37°C with growing medium 
enriched with 2% FBS. The final concentration of LV-VSV-G with cells was 105 TU/ml whereas 
NPs’ concentration ranged from 0.1 µg/ml (0.1 nM, ≅1010 NPs) to 100 µg/ml (100 nM, ≅1013 NPs). 
Subsequently cells were harvested and fixed in 1% PFA and analysed by FACS for the expression 
of GFP. Transduction efficiency was calculated as the percentage of GFP+ cells over the total number 
of cells analysed. Cells with no virus were used as negative control whereas cells incubated with 
only virus, without NPs, was used as positive control. 
 
 
Virus + NPs
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4.3.1 LV-VSV-G !
The first antiviral assay was carried out with pseudotyped lentivirus presenting the envelope 
glycoprotein of the Vesicular Stomatitis Virus (VSV-G). LV-VSV-G was chosen as viral 
model for this study for both its specificity toward sulfates as attachment receptors and for 
its broad tropism (Copreni et al. 2006; Durand & Cimarelli 2011). The assay was performed 
incubating LV-VSV-G for 1h at 37°C with increasing concentrations of the two kinds of 
sulfonate presenting NPs: MUS and MUS:OT. Subsequently, LV-VSV-G was delivered to 
permissive cell in the presence or absence of NPs (as a control) and GFP protein expression 
was evaluated. This first assay was conducted in HeLa cells as model of adherent cell line. 
As it can be observed from the dose-response plot (Figure 8a), both kinds of NPs  revealed 
to be effective inhibitors of LV-VSV-G in HeLa cells. The most effective particles were 
MUS:OT NPs (Figure 8b), which displayed an IC50 of 1 µg/ml (1 nM). MUS particles 
(Figure 8c) were also able to inhibit LV-VSV-G but less efficiently than MUS:OT particles. 
Indeed, the concentration of MUS NPs required to reach the half maximal inhibitory 
concentration resulted twice compared to MUS:OT NPs, 2.4 µg/ml (2.4 nM).  
 
!
 
Figure 8. LV-VSV-G inhibition assay with sulfonated NPs (MUS:OT, MUS). 
(a) LV-VSV-G expressing GFP was incubated for 1h at 37°C with increasing concentrations of MUS 
MUS:OT NPs
MUS NPs
b
c
a
Au
Au
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(squares) or MUS:OT (circles) NPs prior to infection. Cells were analysed by FACS 48h post 
transduction. Transduction efficiency of lentiviral vector was affected by the presence of NPs. 
MUS:OT displayed an IC50 of 1 µg/ml (95% CI 0.7- 1.3 µg/ml)  whereas MUS had IC50 value equal 
to 2.4 µg/ml (95% CI 1.9 - 3.3 µg/ml). Both IC50 values represent the final concentration in HeLa 
cells. Enlarged are depicted the schematic representation of (b) MUS:OT and (c) MUS NPs. 
 
Despite the effectiveness of both structured (MUS:OT) and unstructured (MUS) NPs in 
inhibiting LV-VSV-G, the former was chosen for the successive inhibition studies, owing to 
their unique physicochemical properties as well as for their better inhibitory profile. 
Therefore, to prove that MUS:OT NPs could efficiently inhibit the transduction of LV-VSV-
G on other cell types in a cell-independent way, similar inhibition experiments were 
performed in two different cell lines: HT-1080 and Jurkat cells. In particular, the use of 
Jurkat cells (immortalized T lymphocytes) were chosen as model of suspension growing 
cells.  As it is shown in Figure 9, sulfonated NPs were found to inhibit the transduction of 
LV-VSV-G in both cell lines, with values of IC50 of 3 µg/ml (3 nM) and 2 µg/ml (2 nM) for 
Jurkat and HT-1080 cells respectively.  
 
!
 
Figure 9. LV-VSV-G inhibition assay with MUS:OT NPs in different cell lines. 
Transduction efficiency of LV-VSV-G was evaluated after incubation with increasing concentrations 
of MUS:OT NPs for 1h at 37°C. Virus/NPs mixture was then added to permissive cell lines. 
MUS:OT inhibited LV-VSV-G transduction in (a) Jurkat cells with IC50 = 2.6 µg/ml (95% CI 1.4 - 
4.7 µg/ml) and in HT-1080 (b) with IC50 = 1.9 µg/ml (95% CI 1.1 – 3.2 µg/ml). 
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Having assessed the potent inhibitory activity of MUS:OT NPs in different cell lines with 
different growing conditions and with a different expression of cell membrane proteins, it 
was essential to exclude that the antiviral effect observed was not determined by the presence 
of the MUS itself. For comparison, an antiviral assay was run under similar experimental 
conditions using two concentrations of the soluble MUS ligand, at 0.1 µg/ml (250 nM) and 
1 µg/ml (2.5 µM) in HeLa cells (Figure 10a). These amounts had been determined by 
thermogravimetric analysis (TGA) (Verma et al. 2008) as the same or ten times higher 
quantities of MUS that is present on MUS:OT NPs, at the IC50 concentration. As shown in 
Figure 10a, soluble MUS was found to be completely ineffective as antiviral at both 
concentrations tested. This control experiment suggested that only when the ligands were 
bound to the NPs they could efficiently act as antivirals. Furthermore, the inhibitory ability 
of MUS:OT NPs against LV-VSV-G was compared to an antiretroviral drug (AZT). Figure 
10b shows that AZT could inhibit LV-VSV-G in a nanomolar range (80 nM), underlying the 
potential use of MUS:OT NPs as efficient antiviral.  Similarly, to further confirm the 
antiviral activity of sulfonated MUS:OT NPs, other two control experiments were 
performed. Firstly, LV-VSV-G was incubated with Au-NPs, having roughly the same size 
of MUS:OT and their surface was functionalized with non-sulfonated ligands: EG2-OH 
coated NPs. This kind of NPs did not produce any inhibitory effect upon LV-VSV-G 
infection in HeLa cells (Figure 10c). The number of transduced cells remained 
approximately the same compared to the virus not incubated with NPs, even at 100 µg/ml 
(100 nM), the highest concentration tested. In the second set of control experiments, 
MUS:OT NPs were assayed for their antiviral ability against Ad5, a virus that exploits other 
attachment receptors on their target cells (Figure 10d). In this case, sulfonated NPs failed to 
inhibit Ad5 at any of the concentrations tested. Taken together, these results suggested that 
only sulfonated NPs exerted an antiviral activity which is in turn restricted only to those 
viruses binding to HSPGs as attachment receptors (e.g. LV-VSV-G).  
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Figure 10.  Experiments to validate antiviral activity of MUS:OT NPs. 
Percentage of transduced cells was calculated by FACS after 48h. (a) The inhibition efficiency of 
MUS:OT NPs (red bar) for LV-VSV-G was compared to the use of the soluble MUS ligand (grey 
bars). LV-VSV-G was not inhibited by the ligand itself either using the same amount of MUS present 
in the MUS:OT NPs (light grey bar) nor with ten times higher concentration (dark grey bar). (b) 
Antiviral assay was performed incubating LV-VSV-G with antiviral drug (AZT). Calculated IC50 of 
AZT (80 nM) was in the nanomolar range as for MUS:OT NPs (c) LV-VSV-G transduction 
efficiency evaluated after incubation with increasing amount of non sulfonated NPs (EG2-OH) and 
(d) Ad5 transduction efficiency evaluated after incubation with MUS:OT NPs. 
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4.3.2 HSV-1/2 and HPV-16 PsV !
On the basis of these results, the antiviral activity of MUS:OT NPs was tested with other 
viral systems (not engineered viruses), that selectively recognize HSPGs as first cell 
attachment receptors. The antiviral assays were performed in the molecular virology 
laboratory in collaboration with Prof. Lembo at the University of Turin. Two human 
pathogenic viruses: wild-type HSV (type 1 and type 2) and HPV-16 PsV where selected for 
the inhibition study. The same experimental procedure of the inhibition assay used for LV-
VSV-G (pre-infection incubation of NPs and viruses) was applied to HSV-1/2 and HPV-16 
PsV. As it is shown in the dose-response curves (Figure 11), MUS:OT NPs were able to 
diminish the percentage of infected cells (Vero and 293TT cells) in a dose dependent 
manner. Regarding HSV viruses, type 2 was inhibited more efficiently than HSV-1 by 
MUS:OT NPs with an IC50 of 2 µg/ml (2 nM) and 11 µg/ml (11 nM), respectively (Figure 
11a, b). Similarly, HPV-16 PsV was inhibited by MUS:OT NPs displaying an IC50  of 4 
µg/ml (4 nM) (Figure 11c).  
 
!
 
Figure 11. Antiviral assay of HSPG-binding viruses with MUS:OT NPs. 
The antiviral assay with increasing amounts of MUS:OT NPs was performed on (a) HSV-1 (b) HSV-
2 (c) HPV-16 PsV. 
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4.3.3 LV-gp160 !
Having assessed the ability of sulfonated NPs to drastically reduce the infection of wild-type 
human pathogenic viruses binding HSPGs (e.g. HSV-1 and HSV-2), MUS:OT NPs were 
assayed for their inhibition ability respect to pseudotyped lentivirus exposing the envelope 
protein of HIV (gp160) (Figure 12a). The gp160 glycoprotein, which is comprised of gp120 
and gp41 subunits, is needed for the initial attachment of HIV on target cells through 
multivalent interactions with HSPGs. LV-gp160 particles were produced using a plasmid 
for the gp160 Env protein from the HXB2 strain of HIV. The gp160 Env plasmid was kindly 
donated by Prof. Didier Trono (Laboratory of virology and genetics at École Polytechnique 
Fédérale de Lausanne - EPFL). In order to demonstrate that the viral particles expressed the 
gp160 protein on their capsid, a SDS-PAGE gel was run in parallel with LV-gp160 and LV-
VSV-G and western blot analysis was performed using antibodies directed against two key 
lentiviral proteins: p24, that is the inner capsid protein and gp120 or VSV-G, the 
glycoprotein exposed on the membrane of the viruses (Vandermeulen et al. 2012) (Figure 
12b). As expected, both pseudotyped lentiviruses expressed the constitutive capsid protein 
(p24). On the other hand, the Env gp120 protein was detected only in LV-gp160 viruses 
while the VSV-G protein was present exclusively on LV-VSVG particles. After 
demonstrating the expression of gp160 on lentivirus envelope, we selected the appropriate 
cell line susceptible to HIV, and thus to LV-gp160, infection. Hela T4+ cells were chosen 
for the antiviral assay because they express CD4, which is the primary binding receptor of 
HIV, responsible for its internalization during the process of infection. The expression of the 
CD4 on Hela T4+, was confirmed by FACS analysis using a fluorescent anti-CD4 antibody. 
As expected, HeLa T4+ cells resulted positive for CD4 (99.60%) while HeLa cells, used as 
a negative control, were completely negative for its expression (Figure 12c). Moreover, to 
confirm that LV particles were correctly assembled, LV-VSV-G was further purified 
through sucrose cushion and analysed by DLS. Results showed that LV-VSV-G had a 
uniform distribution and average diameter of about 150 nm according to previously reported 
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papers  (Vandermeulen et al. 2012) (Figure 12d). 
 
 
 
 
 
 
Figure 12. Characterization of LV-gp160 and HeLa T4+ cells. 
 (a) Comparison between LV-VSV-G and LV-gp160 with enlarged envelope glycoproteins (VSV-G 
and gp160). (b) Western blot analysis of envelope glycoproteins for both type of pseudotyped 
lentiviruses and (c) FACS analysis of HeLa T4+ for the expression of CD4. HeLa cells were used as 
negative control. (d) % Intensity (a.u.) vs hydrodynamic diameter (nm) by DLS of LV-VSV-G in 
PBS at room temperature.  
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Following the same experimental procedure as before, an inhibition assay of LV-gp160 
incubated with or without MUS:OT NPs for 1 h 37°C and delivered to HeLa T4+ cells was 
performed. As it can be seen in Figure 13, sulfonated NPs were effective in inhibiting the 
LV-gp160 transduction at the concentration tested of 100 µg/mL (100 nM). In contrast, Au-
NPs with non-sulfonated ligands (EG2-OH NPs), used at the same molar concentration, had 
no effect on LV-gp160 and the number of transduced cells resulted similar to the control 
virus without NPs.  
 
 
 
Figure 13. Confocal Laser Scanning Microscopy (CLSM) images of LV-gp160 incubated with 
NPs. 
LV-gp160 was incubated with 100 µg/ml (100 nM) of MUS:OT or EG2-OH NPs for 1h 37°C before 
delivering the mixture to HeLa T4+ cells. Transduction efficiency, in terms of GFP+ cells 
(fluorescent cells), was evaluated by CLSM after 48h in cells fixed with 2% PFA. Transmitted light 
(upper panels) and green (GFP+, lower panels) channels are shown. Virus without NPs was used as 
a control. 
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4.3.4 AAV2 and AAV5 !
Finally, in order to strengthen the hypothesis of sulfonated NPs as antivirals within the class 
of HSPG-dependent viruses, a control experiment was carried out using one virus (AAV) in 
which two serotypes (AAV2 and AAV5) have different cell surface attachment receptors. 
AAV2 recognizes host cells through HSPGs while AAV5 binds to sialic acid as its primary 
cell attachment receptor. Results showed that the incubation of viruses with MUS:OT NPs 
influenced the capacity of AAVs to transduce CHO-K1 cells in a serotype-dependent 
manner. Serotype AAV2 was almost completely inhibited after pre-treatment with MUS:OT 
NPs, whereas in case of AAV5 no difference in infectivity was observed (Figure 14). These 
first results clearly highlighted the antiviral activity of sulfonated NPs against the subset of 
viruses binding HSPG. However, the antiviral assays could not discriminate whether the 
antiviral activity of the NPs was exclusively due to NPs-virus interactions and so impeding 
the attachment and the recognition of target cells, or whether the NPs were exerting their 
inhibitory ability at the intracellular level by interfering with key processes of the infection 
cycle. In order to further investigate the mechanism through which MUS:OT NPs could 
exert their antiviral effects at different phases of the infection cycle we designed a new set 
of experiments. 
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Figure 14. Confocal Laser Scanning Microscopy (CLSM) images AAVs (AAV2; AAV5) with 
MUS:OT NPs. 
Sulfonated NPs, used at 100 µg/ml (100 nM) and the virus was incubated for 1h at 37°C prior to 
addition to CHO-K1 cells. Transduction efficiency in terms of GFP+ cells was evaluated by CLSM. 
Transmitted light (upper panels) and green (GFP+, lower panels) channel are shown. Virus without 
NPs was used as a control. 
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4.4 Time of addition experiments !
A Time of addition (TOA) assay was performed in order to determine which stage(s) of the 
infectious cycle was affected by the MUS:OT NPs (Figure 15). The possible mechanisms of 
inhibition of sulfonated NPs were investigated using LV-VSV-G as model viral system. 
Therefore, for TOA experiments MUS:OT NPs,  from 0.1 µg/ml (0.1 nM) to 100 µg/ml 
(100nM),  were co-added with viruses (105 TU/ml) during the transduction phase on 
permissive cells, or they were added before (before - b) or after (post - p) LV-VSV-G 
inoculum (Figure 16).  
 
!
 
Figure 15. Schematic representation of the time of addition (TOA) experiments. 
(a) NPs are incubated with cells at different time points before virus inoculum 
(b) NPs are incubated along with viruses (co-addition) 
(c) NPs are added after virus inoculum 
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Initially, MUS:OT NPs were added to cells at 37°C for long (8h) or short (1h) times before 
LV-VSV-G inoculum (Figure 16a). The pre-incubation assay was carried out using 
MUS:OT NPs at 100 µg/ml (100 nM), a concentration that exhibited the best inhibitory 
effects in the antiviral assays. Transduction of LV-VSV-G was not affected by the presence 
of MUS:OT NPs, mainly localized into the cells, and the resultant number of transduced 
cells was comparable to the control without NPs, at all the time points tested (Figure 16a). 
To further understand at which stage of the LV-VSV-G infectious cycle the NPs were able 
to produce their inhibitory effect, TOA experiment was performed adding increasing 
concentrations of MUS:OT NPs during or after (0h or 2h post) LV-VSV-G transduction. 
The ability of MUS:OT NPs to inhibit LV-VSV-G during or after the first two hours of 
transduction was tested on HeLa as well as on HT-1080 cells therefore excluding any 
possible effect dependent upon the cell line used (Figure 16b, c). 
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Figure 16. TOA experiments with MUS:OT. 
 (a) LV-VSV-G transduction efficiency was calculated in HeLa cells treated with MUS:OT NPs at 
100 µg/ml (100 nM) at different times before the virus was delivered to the cells. NPs did not 
determine any reduction in the number of transduce cells when incubated with cells before the virus. 
(b, c) Increasing amounts of MUS:OT NPs (µg/ml) were incubated during (circles), or after, 0h post 
(squares) and  2h post (triangles) LV-VSV-G transduction in HeLa (b) and HT-1080 (c) cells. LV-
VSV-G transduction was inhibited when co-added with MUS:OT NPs independently from the cell 
line used. Percentage of transduction was normalized in respect to untreated LV-VSV-G, used as a 
control  
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Thus, this TOA approach could precisely determine how long the addition of a compound, 
in this case MUS:OT NPs, could be postponed before becoming ineffective. Both 
experiments confirmed that MUS:OT NPs were effective only when co-added with the virus, 
and thus during the first extracellular steps of the infectious cycle, reaching the 50% of 
inhibited cells at a concentration of approximately 10 µg/ml (10 nM). No inhibitory effects 
were observed at 0 or 2h post entry, even at 100 µg/ml (100 nM), the highest tested 
concentration of  MUS:OT NPs. We included in the TOA experiments also an anti-HIV drug 
(AZT) with a well-characterized intracellular mechanism of inhibition (Figure 17a). This 
experiment allowed to assess when and where MUS:OT NPs exerted their antiviral action. 
Consequently, MUS:OT NPs or AZT were incubated before, during and after infection with 
LV-VSV-G (Figure 17b). Our results confirmed that AZT inhibits HIV-1, and consequently 
pseudo-HIV-1 particles like LV-VSV-G, intracellularly by blocking the retrotranscription 
of the viral RNA, that occurs within the first three hours after the virus entry. As it is shown 
in Figure 17b, AZT was able to inhibit LV-VSV-G infection in both phases, before and after 
transduction. When cells were pre-treated with the antiviral drug before virus transduction, 
the percentage of inhibition was proportional to the time of drug exposure of the cells: the 
longer the cells were exposed to AZT, the stronger was the inhibitory effect (Figure 17b). 
Before transduction, long-term incubation of AZT to cells (4h b) was more efficient than 
short-term incubation (10min b) or co-addition during the transduction. On the other hand, 
when cells were treated after transduction, it was obvious that the sooner AZT was added to 
the cells the stronger was the inhibitory effect. In contrast, MUS:OT NPs were found to be 
active only at one time point which was when NPs were co-added along with the virus 
indicating that they interfere only at the initial phases of lentiviral transduction, attachment 
or entry (Figure 17b). 
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Figure 17. Comparison of MUS:OT and AZT antiviral mechanism of action. 
 (a) The hypothesized extracellular inhibition by MUS:OT NPs, was compared to that of the anti-
retroviral drug AZT that acts intracellularly in the TOA experiments. Sulfonated NPs exert their 
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antiviral action interfering with the early steps of the infection (attachment, entry), thus within one 
hour after the virus was delivered to the cells. In contrast, AZT inhibits HIV-1 infection when the 
compound was inside the cell blocking the retrotranscriptase enzyme that converts viral RNA into 
proviral DNA, within the first three/four hours of infection. Image was modified from (Daelemans 
et al. 2011) © Nature Prot. (2011) Nature Publishing Group 
(b) The percentage of GFP transduced HeLa cells by LV-VSV-G was calculated before (b), during 
(co-addition) or after (p) the addition of MUS:OT NPs (red bars) or AZT compound (blue bars). 
MUS:OT NPs used at 100 µg/ml (100 nM) were ineffective when added before or after the infection 
at all time points. 
 
These findings demonstrated that NPs were able to inhibit viral infection acting differently, 
in time and modality, from AZT. In order to determine whether the NPs could inhibit the 
replication of LV-VSV-G affecting the attachment and/or the entry step of the infection, NPs 
were assayed for the inhibition of the attachment and entry step. 
 
4.5 Entry and Attachment Assays !
Once determined that MUS:OT NPs could not block the events downstream LV-VSV-G 
entry, sulfonated NPs were assayed with LV-VSV-G to determine which of the two early 
infection steps (attachment and/or entry) were affected by the NPs (Figure 18). The entry 
and attachment assays were carried out in HT-1080 cells (105 cells/ml) with increasing 
concentrations of MUS:OT NPs from 0.1 µg/ml to 150 µg/ml (0.1 to 150 nM - 1010 NPs/ml 
to 1.5 x 1013 NPs/ml ) (Figure 19).  
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Figure 18. Schematic representation of entry and attachment of LV-VSV-G in presence of 
MUS:OT NPs. 
 (a) MUS:OT NPs were delivered during the attachment phase of LV-VSV-G 
 (b) MUS:OT NPs were incubated during the entry phase of LV-VSV-G 
 
In the attachment assay, MUS:OT NPs and LV-VSV-G were simultaneously added to the 
cells for 1h at 4°C. In such condition (low temperature) endocytic processes are blocked and 
the virus bound to the cell membrane through its attachment receptors could not be 
internalized. Cells were then washed with cold PBS and the temperature increased up to 
37°C for 1h, the time needed for the virus to enter into the cells. A washing step with PBS 
eliminated unspecifically adsorbed virus particles from the plasma membrane. Cells were 
subsequently analysed after 48h for the expression of the reporter gene (GFP). In the entry 
assay, differently from the attachment assay, MUS:OT NPs were added only after virus 
attachment, when the temperature was raised up to 37°C and the virus already started 
entering the cells. Results clearly pointed out that MUS:OT NPs were able to inhibit LV-
VSV-G transduction only in the attachment phase and had no, or very limited, effect on the 
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entry step (Figure 19). Indeed, the percentage of transduced cells during the entry phase was 
almost similar to the control (untreated virus) even at the highest tested concentration of 150 
µg/ml (150 nM). In contrast, the attachment of LV-VSV-G to target cells was affected by 
the presence of sulfonated NPs as shown by the decreased infectivity at the increase of NPs’ 
concentrations.  
 
!
Figure 19. Entry and attachment assays with LV-VSV-G in presence of MUS:OT. 
The percentage of HT-1080 cells transduced by LV-VSV-G was calculated at the entry (diamond) 
or attachment (square) steps with increasing amounts of MUS:OT NPs. Percentage of transduced 
cells was normalized in respect to untreated LV-VSV-G used as control. 
 
4.6 Virucidal Assay !
The aim of the virucidal assay was to assess the ability of MUS:OT NPs to inactivate (make 
not infectious) virus particles, thereby neutralizing viruses’ action, before the infection of 
permissive cells. Briefly, the virus was incubated 2h at 37°C with an effective inhibitory 
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concentration of MUS:OT NPs, > 100 µg/ml (>1013 NPs),  as determined in the previous 
antiviral assays. Subsequently, the virus in presence of NPs was titrated by serial high fold 
dilutions in order to calculate the amount of virus particles that remained infective after the 
incubation step. The virucidal activity of MUS:OT NPs was tested both with HSPG-binding 
viruses (HSV-2, LV-VSV-G) as well as with non HS-dependent viruses (Ad5). The first 
virucidal assay, carried out with LV-VSV-G (Figure 20a), showed that only MUS:OT NPs 
were able to permanently inactivate virus particles after the pre-infection step (2h 37°C) with 
a significant reduction (> 6 log) in the number of viruses particles/ml (transducing units/ml 
- TU/ml). The same assay, performed with EG2-OH NPs, revealed that non-sulfonated NPs 
had no effect on LV-VSV-G particles which number was similar to the control. Similarly, 
LV-VSV-G virucidal assay was carried out with the anti-retroviral drug (AZT). Although 
AZT is able to inhibit LV-VSV-G transduction, it did not determine a reduction in the 
number of infectious particles compared to the untreated virus (Figure 20a). These findings 
highlighted the difference in the mechanism of inhibition between MUS:OT and AZT. 
Indeed, MUS:OT NPs were exerting their antiviral action interacting with viruses’ capsid 
making the virus unable to infect (inactive) even when the mixture NPs/virus was diluted. 
Consequently, the inactivation of LV-VSV-G by contact with MUS:OT was due to tight 
interaction between the two species. On the other hand, AZT compound, inhibiting an 
intracellular viral enzyme (Retrotranscriptase - RT), did not cause a reduction in the number 
of LV-VSV-G particles and thus when diluted it could not impede the transduction of 
viruses. Furthermore, in a control experiment virucidal assay was performed incubating with 
MUS:OT NPs with a non-HS-binding virus (Ad5) (Figure 20b). 
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Figure 20. Virucidal assays of LV-VSV-G and Ad5. 
(a) LV-VSV-G virucidal assay with sulfonated (MUS:OT, red bar), non-sulfonated (EG2-OH, green 
bar) NPs and antiviral drug (AZT, blue bar). Titration of LV-VSV-G after 2h 37°C revealed that 
incubation with MUS:OT (1000 µg/ml – 1 µM) significantly reduced the number of LV-VSV-G 
transducing units/ml. On the contrary, neither EG2-OH (1000 µg/ml – 1 µM) nor the AZT antiviral 
(1.8 µM) were able to diminish the number of virus particles after the incubation. (b) Ad5 virucidal 
assay performed after incubation for 2h 37°C with MUS:OT NPs (red bar) used at a concentration 
of 1000 µg/ml (1 µM).  
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As expected in this case MUS:OT NPs did not determine a decrease in the number of Ad5 
which remained close to the virus not incubated with NPs. This result confirmed the 
mechanism of action of MUS:OT NPs that selectively interact and thus inactivate HSPG-
binding viruses.  
According to the results obtained with LV-VSV-G, we then tested the ability of MUS:OT 
NPs to inactivate HSV-2 wild-type virus. Following the same experimental procedure, the 
assay with HSV-2 showed that MUS:OT NPs could efficiently reduce the number of 
infectious particles (>4 log) compared to the virus not treated with NPs (Figure 21).  
 
!
Figure 21. Virucidal assays of HSV-2 with MUS:OT NPs. 
Virucidal assay was performed after HSV-2 incubation for 2h 37°C with MUS:OT NPs (red bar) 
used at a concentration of  100 µg/ml (100 nM). The number of infectious viruses (PFU/ml), 
calculated by serial high fold dilutions, was drastically reduced after the incubation with sulfonated 
NPs (MUS:OT).  
 
Taken together, these insights indicated that MUS:OT NPs acted as virucides, thus enabling 
the inactivation of HSPG-binding viruses that, after interacting with NPs, were no longer 
able to infect. Next, we wanted to investigate the time needed to MUS:OT NPs to inactivate 
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viruses. Consequently, the number of LV-VSV-G particle was calculated, through titration 
method, after exposure with different concentrations of MUS:OT NPs at different time 
points. Initially, we calculated the titer of LV-VSV-G immediately after (t0) mixing the two 
components (NPs/virus). As shown in Figure 22, at t0 the number of virus particles/ml 
(TU/ml), was reduced of roughly one log after the exposure with the highest concentration 
of MUS:OT NPs (500 µg/ml), highlighting their rapid inactivation kinetics. Similarly, 
incubating LV-VSV-G for longer times (30 min, 60 min, 120 min, 360 min) and with 
increasing amounts of MUS:OT NPs (5, 250 and 500 µg/ml) was observed a reduction in 
the number of virus particles proportional to the concentration and the time of exposure of 
the NPs.  
 
 
Figure 22. Virucidal assays of LV-VSV-G with MUS:OT NPs versus time. 
LV-VSV-G was titrated (through dilution method) after exposure for different times (0, 30, 60, 120, 
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360 min) with increasing concentrations of MUS:OT NPs: 5 µg/ml (5 nM) (orange bars), 250 µg/ml 
(250 nM) (light red bars), 500 µg/ml (500 nM) (dark red bars). 
 
However, the virucidal assay performed could not discriminate whether the viral inactivation 
observed was only due to irreversible coating of the viruses by NPs which prevents the 
recognition of target cells, thereby neutralizing the virus’s infectivity, or NPs were 
destabilizing or dismantling virus particles acting as “molecular nanobullets” thus 
destroying viruses upon contact. To address this issue, we performed Cryo-TEM 
experiments with wild-type HSV-2 to visualize and characterize NPs/virus interactions and 
so to evaluate whether the NPs could permanently bind and inactivate viruses (virustatic) or 
could actually destroy infectious particles (virucidal).  
 
4.7 Cryo-Electron Microscopy (cryo-EM) of HSV-2 and MUS:OT !
Transmission electron microscopy (TEM), from its appearance 80 years ago, continues to 
paly a fundamental role in the discovery, description and understanding of virus particles as 
well as for the identification of unknown viruses and the rapid diagnosis of viral infections 
from clinical specimens (Ying et al. 2013). TEM employs a fine electron beam, created by 
a high-voltage, electric current-heated tungsten filament, focused by magnetic lenses. The 
electron beam passes through an ultrathin plastic section with samples post-fixed in osmium 
and stained with the heavy metals uranyl and lead, which block the beam in proportion to 
their respective degrees of electron density (Graham & Orenstein 2007). The differential 
transmission of the electrons creates the image. TEM allowed to increase the level of 
magnification and resolution up to 0.1 nm and to visualize virus particles that could not be 
seen by light microscopes. In order to visualize viruses as well as biological samples, they 
must be stained with heavy metal salts (negative staining), such as phosphotungstic acid or 
uranyl acetate. Negative staining makes the virus stand out from the background and also 
provides morphological information about virus’ external structure (Roingeard 2008). 
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Although viruses can only be visualized by TEM, the fine detail of viral structure can be 
visible by the rapid freeze and vitrification of viral specimens, examined by cryo-electron 
microscopy (cryo-EM) (Roingeard 2008). This technique is widely used in structural biology 
and allows to quickly create high-resolution models of molecules or enzymes (ribosomes) 
(Callaway 2015). 
 Consequently, since we wanted to investigate the intimate nature of the interactions 
occurring between viruses and NPs, cryo-EM experiments were performed with MUS:OT 
NPs and a wild-type HSPG-binding virus (HSV-2) (Figure 23). Viruses, at a concentration 
of 107 PFU/ml, were imaged after 1.5 h at 37°C with MUS:OT NPs at 200 µg/ml (200 nM) 
and untreated virus was used as a control. Although the study of NPs/virus interactions 
through cryo-EM is still in its initial phase, first preliminary images allowed to elucidate and 
narrow down the mechanism of inhibition of MUS:OT NPs toward HSPG-binding viruses. 
As it is shown in Figure 23, according to the hypothesized mechanism of action, MUS:OT 
NPs do interact with infectious virions. More specifically, HSV-2 particles incubated with 
MUS:OT NPs were always associated with NPs and this tight interaction might be 
responsible for the inhibition observed in vitro.  Indeed, NPs can either completely cover the 
outer surface of the virus or bind to multiple sites onto the capsid. 
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Figure 23. Cryo-EM images of HSV-2. 
HSV2 were imaged after 1.5h at 37°C. (a) HSV-2 virions without MUS:OT NPs. (b, c, d) HSV-2 
particles incubated with 200 µg/ml of MUS:OT NPs. 
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! V. DISCUSSION !
Viral infections represent a continuous threat to global health. The approved drugs employed 
for the treatment of viral diseases, act specifically by blocking viral proteins (e.g capsid 
proteins, viral enzymes) necessary for the infection of host cells. These virus-specific drugs, 
especially those against important human pathogenic viruses, have saved innumerable lives, 
underlining their remarkable success in clinics (Vigant et al. 2015). Despite the undoubted 
achievements of targeted antiviral strategies, the emergence of viral resistance and drug-
related side effects, pointed out the need for the design and development of antiviral 
molecules with a wider activity. To address this challenge, in the present research project 
we investigated the potential use of Au-NPs exposing sulfonate ligands as broad-spectrum 
antiviral agents inhibiting early steps of infection (attachment and/or entry). We 
hypothesized that these NPs potentially interact with the whole subset of viruses that binds 
extracellular sulfates such as heparan sulfates in the glycocalyx on target cells and thereby 
inhibits the infection and the spread of viruses.  
 
5.1 Inhibition of viruses by sulfonate-presenting NPs (MUS, MUS:OT) !
In this project we aim at assessing the ability of sulfonated NPs (MUS and MUS:OT) as 
potential inhibitors of a wide range of HSPG-binding viruses.  
As first preliminary in vitro experiments, it was essential to verify that sulfonated coated 
Au-NPs were not inducing cytotoxicity per se. Cell viability was evaluated by PI staining 
and MTS assay in our cell culture models employing a wide range of working concentrations 
of sulfonated Au-NPs (Figure 6). In both assays, no significant reduction in cell viability 
was associated with the presence of NPs. This first observation allowed to conclude that NPs 
were eligible for the study of virus inhibition with cells. Indeed, it was possible to associate 
the decrease in the percentage of infected cells as a result of the antiviral activity of NPs and 
not as an increase in cell mortality due to their cytotoxic effect (Baram-Pinto et al. 2010). 
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Initially, the inhibitory effect of MUS:OT and MUS sulfonated NPs was evaluated for 
lentiviral vectors by in vitro experiments in HeLa cells. Lentivirus, derived from HIV-1, was 
pseudotyped with the G protein of VSV (LV-VSV-G) and used as viral model both for of its 
ability to infect a wide range of cells and for its relatively low biosafety profile (Durand & 
Cimarelli 2011). In particular, LV-VSV-G was chosen because its broad tropism was 
essential to further support that the inhibitory effect of NPs was not dependent on specific 
target cells. Another important feature offered by the LV-VSV-G model system was that it 
exploited HSPGs to infect cells (Copreni et al. 2006; Copreni et al. 2005). This last feature 
was fundamental to assess the hypothesized antiviral mechanism of action: the inhibition of 
virus infection by sulfonated NPs was based on competition with cellular HSPGs for the 
binding to infectious virions. Furthermore, it allowed to investigate specifically the 
physicochemical interactions between sulfonated NPs and viral particles and thus evaluate 
their ability to block the first crucial steps of the infectious process (attachment and entry 
phases). The first in vitro antiviral assays, conducted in a permissive cell line (HeLa), was 
carried out incubating LV-VSV-G with increasing amounts of both kinds of sulfonated NPs 
(MUS and MUS:OT) for 1h at 37°C prior infection (Figure 8). We observed that both 
sulfonated NPs were able to inhibit Lentivirus transduction of their target cells. The ability 
of MUS:OT to inhibit LV-VSV-G was not restricted only to one cell line (HeLa) but it was 
also confirmed in other HS-presenting cell models (Jurkat and HT-1080), (Fig. 9). 
Next, to corroborate our findings we included in our study a set of cross-control experiments 
testing 1) that lentivirus was not inhibited by non-sulfonated Au-NPs (EG2-OH NPs) of the 
same size of MUS:OT and 2) whether MUS:OT NPs could also inhibit non-HS-binding 
viruses. As shown in Figure 10c, LV was not inhibited by EG2-OH NPs, even at the highest 
concentrations. This finding further supported our initial results showing that the exposed 
functional groups (SO3-) on MUS:OT NPs and in particular the spatial arrangement of MUS 
molecules bound on the NPs’ surface were essential for the observed inhibitory activity. In 
parallel, to assess the inhibitory ability of MUS:OT NPs on viruses that do not require 
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HSPGs for the attachment to host cells,  we assayed MUS:OT NPs in presence of Adenovirus 
serotype 5 (Ad5), (Figure 10d). The replication-defective Ad5,  a double-stranded DNA 
virus widely used for gene therapy in human diseases (Tatsis & Ertl 2004), was the ideal 
candidate to test our hypothesis because of its inability to bind HSPGs. Indeed, Ad5 infects 
target cells through the binding of a primary receptor used also by Coxsackie B virus, termed 
the Coxsackie and Adenovirus receptor (CAR) (Bergelson 1997). As reported by many 
studies, Ad5 is not able to bind CAR-defective cells as the Chinese hamster ovary (CHO) 
cells (Roelvink et al. 1998; Davison et al. 1999). As expected, the inhibition assay revealed 
that MUS:OT NPs did not induce any reduction in the number the of transduced cells by 
Ad5 (Figure 10d). These results proved that the antiviral activity of sulfonate exposing NPs 
was limited to lentivirus, which required HSPG to infect cells, while no effects were 
observed in the case of the Adenovirus vector. 
It can be summarized that MUS:OT NPs, showed a superior antiviral effect on LV-VSV-G 
compared to MUS NPs. Inhibition assays conducted with MUS:OT in all in vitro models 
pointed out: 1) a high specificity of NPs toward lentiviral particles, leading to IC50 values in 
the range of nanomolar concentrations and 2) the versatility of MUS:OT NPs as antiviral 
system, since their effectiveness was comparable in all the cell lines tested. The peculiar 
surface composition of the amphiphilic Au-NPs, that contained MUS and OT ligands, 
compared to homoligand shell NPs (MUS NPs) (Jackson et al. 2004) could explain the 
enhanced ability of MUS:OT NPs to inhibit lentiviruses. Specifically, the repetitive pattern 
of hydrophobic and hydrophilic molecules on MUS:OT NPs seems to fit better the sulfate 
binding site on the virus capsid than the completely sulfonate ones (MUS NPs) and hence 
induce a stronger binding.  
Another important issue, that required further investigation, was the role of MUS ligand 
alone in the inhibition of Lentivirus. Therefore, in order to assess whether the antiviral 
efficacy of NPs functionalized with multivalent MUS molecules was due to their 
arrangement on the surface or not, we compared the effect of the soluble MUS ligand in 
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presence of LV-VSV-G. MUS ligand was found to be completely ineffective in inhibiting 
the lentivirus, compared to the same amount bound to the NPs (Figure 10a). This control 
experiment suggested that only ligands bound to a NP and hence organized in a precise 
pattern and distance act as antivirals, emphasizing the importance of the spatial orientation 
of functional groups on the surface of NPs. Moreover, this finding underlined that 
multivalent interactions achieved with the use of NPs, were crucial for effectively engaging 
viral proteins and inhibit infection. Thus, the use of functionalized NPs, capped with 
molecules resembling natural viral receptor such as MUS, rather than molecules in solution, 
was found to be a promising tool eligible for the development of antivirals especially 
considering the low quantities (nM) needed to inhibit virus infection. Our results with 
sulfonated Au-NPs as viral inhibitor were in accordance with similar previous studies 
conducted by Baram-Pinto and co-workers (Baram-Pinto et al. 2010). In their study, they 
compared, through a plaque-reduction assay, the antiviral efficiency of Au-MES NPs respect 
to the ligand molecules (soluble MES) bound to the NPs. They reported a complete 
inhibition of wild-type HSV-1 McIntyre strain in Vero cells, obtained with Au-MES NPs, 
while no reduction in virus infectivity was observed when using the same amount of free 
MES. The outcome of their experiments allowed them to conclude that the antiviral effect 
was specifically due to MES functionalized NPs, whereas the two components taken on their 
own (unmodified Au-NPs and soluble MES ligands) did not inhibit HSV-1 infection 
(Baram-Pinto et al. 2010).  
Having assessed the role of MUS:OT in inhibiting LV-VSV-G transduction, MUS:OT NPs 
were tested on several human pathogenic viruses using HSPGs as first step for virus 
infection, such as wild-type HSV-2, HSV-1 and HPV-16 PsV. These set of experiments were 
conducted in the laboratory of molecular virology in collaboration with Prof. David Lembo’s 
group at the University of Turin, Italy. The inhibition assays run with MUS:OT NPs clearly 
showed that MUS:OT NPs could prevent the infection of target cells in the same range of 
concentrations (1-10 nM) as for initial lentivirus experiments (Figure 11). The efficacy of 
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MUS:OT NPs highlighted their inhibitory property also in wild-type models, further 
validating their potential use as broad spectrum agents against HSPG-binding viruses. 
Similarly, to the control experiment performed with LV-VSV-G, HSV-1, HSV-2 and HPV-
16-VLP were incubated with only MUS soluble ligand, which was found to be ineffective 
in the inhibition the viruses (data not shown). In light of the results obtained with these 
important human viral pathogens, we wanted to extend our study to HIV-1, the viral 
pathogens responsible for the acquired immunodeficiency syndrome (AIDS), known to 
interact with membrane HSPGs (syndecans) for the adsorption and susbequent infection of 
its major target cells in vivo: macrophages (Saphire et al. 2001). Considering that the study 
of infectious replicative-competent HIV-1 viruses requires certified laboratories that can 
deal with class III hazard infectious substances (Prokofjeva et al. 2011), in our study we 
developed and used pseudo-HIV-1 lentiviral particles as safe model for the study of 
MUS:OT NPs against wild-type HIV (Figure 12). Such lentiviral-based HIV-1 model have 
been used by many researchers as safe approach for the screening of anti-HIV drugs 
(Prokofjeva et al. 2011; Garcia-Perez et al. 2007). The antiviral activity of MUS:OT NPs 
was thus tested with pseudo-HIV-1 particles which are lentiviruses expressing the envelope 
glycoprotein of HIV (gp160) and thus structurally, but not genetically, similar to the native 
virus and available for laboratory use (biosafety level 2 – BSL2). The antiviral assay 
confirmed that MUS:OT NPs were able to inhibit the pseudotyped-gp160 lentivirus (LV-
gp160) (Figure 13). Altogether these results supported the antiviral ability of MUS:OT NPs 
toward sulfonate binding viruses. Finally, the initial hypothesis that MUS:OT NPs could 
selectively inhibit viruses binding sulfates on cell membrane by mimicking the natural viral 
receptor, was validated by the experiment with two serotypes of Adeno-associated virus 
(AAV2 and AAV5). We found inhibition of AAV2 that exploits HSPGs as attachment 
factor, and no effect was observed with AAV5 that binds sialic acid, which supported the 
proposed mechanism of interaction of the NPs (Figure 14).  
The use of nanoscale materials like NPs as potential antiviral agents is an expanding field of 
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research. NPs represent an attractive tool to fight viral infections owing to their unique 
physicochemical properties, such as their size and their high surface-volume ratio, which 
offers more contact area for the attachment of ligands and active molecules. Several recent 
papers have reported that metal-based NPs, in particular Au-NPs and Ag-NPs functionalized 
infectious cycle, specifically the attachment and entry processes (Baram-Pinto et al. 2009; 
Elechiguerra et al. 2005). Indeed, NPs can be coated with molecules mimicking natural viral 
receptors, thus engaging multivalent interactions with virions that inhibit/prevent 
recognition and infection of the target cell. This strategy has been validated in many studies 
where metal nanoparticles have been proven to be effective antivirals agents against several 
types of viruses: HIV, HSV type 1, monkeypox virus (Lara et al. 2010; Lu et al. 2008; 
Baram-Pinto et al. 2010; Rogers et al. 2008). An example is the the study conducted by Papp 
and co-workers (Papp et al. 2010). They observed that influenza virus infection was inhibited 
by using nanoparticles functionalised with sialic acid (SA)-terminated glycerol dendron that 
resembled the natural viral receptors on the surface of the host cell. They found that the 
ability of influenza virus to bind target cells was affected by the use of nanomolar 
concentrations of 14 nm sialic-acid Au-NPs.  
 
5.2 Antiviral mechanism of action of MUS:OT NPs  !
5.2.1 Time of addition !
The inhibition assays pointed out a selective inhibitory ability of MUS:OT NPs toward those 
viruses binding HSPGs as primary attachment receptor. However, the limit of the inhibition 
assay experiments was that they could not discriminate whether NPs were exclusively acting 
at the initial stage(s) of the transfection process (attachment). Another mechanism that could 
explain the reduced number of transduced cells was NPs’ interference with intracellular 
replication processes that occur within the cytoplasmatic matrix, for example uncoating and 
replication. Indeed, as reported by Verma et al. (Verma et al. 2008), MUS:OT NPs could 
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passively penetrate the cell membrane, even when the endocytosis is blocked. This could 
indicate an intracellular inhibition especially in the light of the lower efficiency of MUS 
NPs, which can only penetrate cell membrane through endocytic routes. In order to 
understand at which stage(s) of the infection MUS:OT NPs exerted their antiviral activity, 
several experiments were performed, using LV-VSV-G as viral model. First, to assess 
whether MUS:OT were able to block the infection intracellularly, HeLa cells were 
preincubated with NPs for time points (8, 4, 2, 1, 0.5 hour) at 37°C before delivering 
lentiviral particles. It was observed that NPs already internalized into the cells did not 
produce any inhibitory effect (Figure 16a) resulting in the number of transduced cells 
comparable to the untreated control.  
Next, time-of-addition (TOA) experiments were carried out to explore whether MUS:OT 
NPs interact with the virus during or after fusion with the cells. To address this issue, 
MUS:OT NPs were delivered to cells, HeLa and HT-1080, (Figure 16b, 16c) along with LV-
VSV-G (co-added) or after the transduction (0h or 2h post transduction). In both cell lines, 
MUS:OT NPs had an antiviral effect on the transduction efficiency of LV-VSV-G only when 
they could interact with virions outside the cells. The addition of the NPs immediately after 
the transduction (0h p) or 2h after, did not affect the percentage of transduced cells compared 
to the untreated control (Figure 16b, 16c).  
These findings indicate that MUS:OT were only exerting their antiviral action through direct 
interactions with virions but they could not stop any replicative process inside the cell. In 
order to validate these results, we carried out TOA experiment under similar experimental 
conditions by comparing the hypothesized antiviral mechanism of MUS:OT NPs with AZT 
(Figure 17), a well characterized non-nucleoside retrotranscriptase inhibitor. This inhibitor 
interferes with a viral enzyme intracellularly at a well-defined time point (2-3 hours after 
infection) in the virus replication cycle. As expected, the anti-retroviral drug AZT could only 
inhibit the transduction of LV-VSV-G when added within four hours post infection or long 
before the infection (3h), meaning that the compound could not stop the retrotranscriptase if 
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incubated for short times with the cells (10 min). On the other hand, NPs did not determine 
any effect neither before nor after the infection, in accordance to what we observed 
previously, while they could efficiently inhibit transduction when they were co-added with 
lentiviral particles. These findings allowed to conclude that although MUS:OT NPs could 
easily penetrate the cells, they were not able to interfere with post-fusion replicative events.  
 
5.2.2 Entry vs attachment assay !
In order to understand whether the entry and/or the attachment of LV-VSV-G could be 
involved in the mechanism of MUS:OT inhibition we performed attachment vs entry assay. 
We found that MUS:OT NPs were able to interfere with the attachment and only partially 
during the entry step (Figure 19). These findings confirmed our hypothesis that sulfonated 
MUS:OT NPs can act as competitive antagonists for viruses binding to HSPGs on target 
cells.  
Nevertheless, these two assays could not determine whether MUS:OT NPs:  
1.! bind irreversibly to the virions and hence block the recognition of HSPGs on cell 
surface, 
2.! engage weak interactions with the virions, hence upon certain conditions (dilutions) 
they regain infectivity, 
3.! were bound to viral glycoproteins as well as to viral membrane inducing some 
conformational changes which rendered the virus not infectious,  
4.! interact strongly with virions destroying them and resulting in a virucidal action.  
As reported in literature, we considered other possible mechanisms such as viral inhibition 
by interactions between NPs and viral nucleic acids. For example, Lu et al. have reported 
that Ag-NPs of about 10 nm could both interact with Hepatitis B virus (HBV) as well as 
bind to the viral DNA, thereby impeding virus replication. Summarizing our results, we can 
conclude that the most likely sites for MUS:OT NPs and virus interactions were viral 
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envelope glycoproteins and no post-entry interaction leads to inhibition of the virus. 
 
5.3 Virus inactivation by MUS:OT NPs !
In order to characterize the nature of NPs/virus interactions we performed the virucidal 
assay. Virucidal experiments were conducted with pseudotyped lentivirus (LV-VSV-G) as 
well as with HSV-2 wild type virus after incubation with MUS:OT NPs for 2h at 37°C. We 
observed that the amount of viruses able to infect cells, calculated by serial dilutions of the 
NPs/virus mixture (titration method), was drastically reduced (Figure 20a, 21). These 
findings confirmed that sulfonated NPs were acting through a direct binding to viruses’ 
external structure thus rendering them no more infectious (inactive). Moreover, the 
experiment allowed to exclude that interactions between NPs and viruses were reversible. 
Indeed, although the hypothesized mechanism of interaction was based on weak electrostatic 
interactions, MUS:OT NPs were able to permanently inactivate viruses once they 
encountered HS-binding viruses even after dilution. Consequently, if interactions had been 
weak, NPs would have been detached from viruses’ surface once diluted and thus the number 
of viruses able to infect the cells would have been the same as in the untreated control (Figure 
24). Moreover, virucidal assay performed with MUS:OT NPs and non-HS binding virus 
(Adenovirus) (Figure 20b) or non-sulfonated NPs (EG2-OH NPs) and LV-VSV-G (Figure 
20a) showed no decrease in the number of virus particles.  
Next, we investigated the effect of MUS:OT NPs at different incubation times and with 
increasing concentration of MUS:OT NPs (Figure 22). Results showed that the decrease in 
the number of infectious viruses was directly proportional to the incubation time and 
concentrations tested. This finding allowed to hypothesize that MUS:OT and viruses were 
interacting through tight binding, which have in turn impeded the recognition of the host cell 
(by physically block virus receptors) or disrupted virus structure. In particular, the reduced 
number of virus particles, calculated within the first minutes of incubation with NPs, 
 ! 94 
highlighted the potential ability of MUS:OT NPs as virucidal agent which by definition act 
quickly and effectively in preventing infection of vulnerable target cells (Lara et al. 2010; 
Borkow et al. 1997).   
 
 
 
!!!!
Figure 24. Virucidal assay with MUS:OT NPs and possible mechanisms of virus inactivation. 
Once viruses are delivered to cells together with NPs they could not attach to target cells owing to 
the interactions between virus envelope glycoproteins and NPs.  
Diluting Virus/NPs mixture, virus could: 
(1)! regain its infectivity, if interactions were weak 
(2)! remain non infectious (inactivated), because NPs engage tight binding to envelope 
glycoproteins. In this way, the virus maintains its structural conformation but can not 
recognize target cells (virustatic effect) 
(3)! be inactivated due to changes in its structural conformation and thus can not recognize target 
cells and infect them (virustatic effect) 
(4)! be destroyed upon contact with NPs (virucidal effect) and thus can not infect target cells 
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Based on the in vitro virucidal experiments, we could narrow down the mechanisms through 
which NPs could inactivate a virus. We could exclude inactivation by weak interactions that 
only interfere with the recognition of the cellular binding site, because by diluting NPs/virus 
mixture we did not observe any transduced cells. These results suggested that the inhibitory 
effect of MUS:OT NPs was due to tight NPs/virus interactions which could not merely 
impede the recognition of target cells by mimicking the natural attachment receptors. The 
binding of NPs to specific sites on the outer surface of HS-binding viruses, presumably on 
those glycoproteins responsible for the recognition of target cells, was also shown by other 
researchers, e.g. on Ag-NPs with anti-HIV ability (Elechiguerra et al. 2005; Lara et al. 2010). 
Researchers observed that NPs within a certain size range (1-10 nm) could efficiently 
interact with specific sites on the viral envelope and inactivate infectious HIV-1 particles. 
These studies (Elechiguerra et al. 2005; Lara et al. 2010) pointed out that the spatial 
arrangement of the Ag-NPs on HIV-1 virion, can be explained by a preferential binding on 
the Ag-NPs with gp160 viral envelope glycoproteins, in particular with its gp120 subunits. 
Following the hypothesis reported in literature, we assume that the ability of MUS:OT NPs 
to inactivate several types of viruses could be mainly driven by electrostatic interactions with 
those positively charged amino acids on viral glycoproteins that recognize HSPGs on target 
cells. Therefore the activity of MUS:OT NPs must be universal to all HS-binding viruses. 
 
5.4 Cryo-EM study of the NP/virus interaction !
Cryo-EM experiments were carried out to elucidate the type of interaction occurred between 
MUS:OT with a HS-binding virus (e.g HSV-2) (Figure 23). Our cryo-EM images showed 
that NPs were found to be diffusely attached to HSV-2 virions and hence indicated that a 
tight NPs binding leads to inactivation of infectious HSV-2. Thus cryo-EM allowed to 
narrow down the mechanism of action to two possible mechanisms of viral inactivation: 1) 
MUS:OT NPs binds to HSV-2 on its surface glycoproteins in an irreversible way that 
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permanently block the virus or 2) MUS:OT NPs could engage tight interactions with HSV-
2 virion that lead to important conformational changes at HSV-2 structure with a resultant 
inability of the virus to recognise and infect target cells. Although cryo-EM indicated to one 
of the aforementioned mechanisms for HSV-2 inactivation, also a third mechanism is 
possible. We hypothesize that MUS:OT NPs interaction with viruses’ capsid is so strong 
that it not only leads to conformational changes but also to a rupture of the virus. This 
possibility is still under investigation. Broglie and co-workers (Broglie et al. 2015) reported 
that gold/copper sulphide (Au/CuS) NPs can rapidly inactivate Norovirus virus-like particles 
(VLP). They suggested that NPs treatment determined capsid protein degradation and 
consequently the damage to VLPs explained by virus inactivation. Moreover, they found 
that treatment with high concentrations of Au/CuS NPs (83 µM) could break Norovirus 
VLP’s capsids into fragments with no evidence of structurally intact VLPs.  
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! VI. CONCLUSIONS AND FUTURE OUTLOOK !
The use of HSPG as docking site for the attachment of a large variety of human pathogenic 
viruses, such as HIV, HPV, HSV, CHIKV, Ebola and Dengue (WuYang et al. 2011; 
Salvador et al. 2013; Gardner et al. 2014) makes surface engineered NPs, coated with 
sulfonates, an attractive wide–spectrum antiviral with potential virucidal properties. In 
particular, the efficacy of MUS:OT NPs against such broad range of viruses suggests their 
valuable use as novel therapeutic agent as well as a key component of new microbiocidal 
materials. The proposed antiviral mechanism of action is given by to the characteristic 
arrangement of the ligands on the surface of NPs.  
Differently from other studies conducted on sulfonate-capped NPs, MUS:OT NPs showed 
not only antiviral (blocking), but also virucidal (destructive), effect toward a wide range of 
HS-binding viruses at very low concentrations. Their future application can range from 
topical microbicide e.g. in form of a cream or gel which can prevent the infection with 
sexually transmissible viral diseases, to surface constituent of materials that would prevent 
virus transmission (e.g. air filters, protective garments). Au-NPs are an extremely versatile 
model that easily enables fine-tuning of surface properties; however, their non-negligible 
cost is a main drawback that prevents translation into a cheap and far-reaching technology. 
For this reason we planned to engineer NPs with the same surface characteristics as MUS:OT 
but with a different core such dendrimers, silica, iron oxide. 
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